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ABSTRACT 
Sedentary lifestyles and poor dietary choices are the major cause of the global increase in the 
prevalence of obesity and metabolic dysfunction in children. The high cost and limited access 
to conventional drugs by poor communities make them depend on ethnomedicines. Terminalia 
sericea (T. sericea) contains phytochemicals that give its extracts hypolipidaemic and 
hypoglycaemic properties hence its use in ethnomedicine to treat diabetes mellitus. Using 
weanling Wistar rat pups fed a high fructose diet to model growing children exposed to high-
sugar diets, this study sought to evaluate the effects of aqueous T. sericea leaf extracts on their 
growth performance, glucose homeostasis, visceral morphometry and their general health 
profile. Forty 21-day old male Wistar pups were randomly allocated to five treatment 
regimens. Each group had ad libitum access to a commercially supplied rat chow. Group 1 
pups were given plain drinking water and plain gelatine cubes, group 2: 12% fructose solution 
and plain gelatine cubes, group 3: 12% fructose solution and gelatine cubes containing 
fenofibrate at a dosage of 100 mg.kg
-1
 per day, group 4: 12% fructose solution and gelatine 
cubes with a low dose (100 mg.kg
-1
 per day) of the T. sericea extract and group 5: 12% 
fructose solution and gelatine cubes with a high dose (400 mg.kg
-1
 per day) of the T. sericea 
extract. The pups were maintained on the regimens for 12 weeks after which they under went 
an oral glucose tolerance test. Fasting blood metabolite content was then determined after 
which the rats were killed and tissues collected for visceral morphometrical, linear growth and 
surrogate markers’ of health determinations.  
 
T. sericea extracts had no negative effect on growth performance (body mass and indexes of 
long bone growth) but rats given fenofibrate had lighter empty carcasses and shorter tibiae. 
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The administration of T. sericea extracts neither improved glucose homeostasis nor caused 
derangement of glucose handling by rats given a high fructose diet following an oral glucose 
challenge. However, the administration of fenofibrate to rats given a high fructose diet 
resulted in decreased glucose handling following an oral glucose challenge. With the 
exception of the administration of fenofibrate which resulted in a significantly high (P < 0.05) 
fasting blood glucose concentration, treatment regimens had no effect on fasting blood 
glucose, triglyceride and cholesterol concentrations. Rats given fructose with either plain 
gelatine cubes or low T. sericea dose had significantly higher (P < 0.05) liver lipid content 
compared with the control treatment. Administration of T. sericea extracts to rats given a high 
fructose diet had no effect on the GIT, other abdominal viscera and markers of general health. 
The administration of fenofibrate to rats given a high fructose diet caused increased relative 
mass of GIT organs (stomach, small intestine and caecum), increased absolute mass of other 
viscera (liver and kidney); increased serum phosphorus and alkaline phosphatase 
concentration. 
 
Results from the study revealed that administration of a high dose of aqueous T. sericea leaf 
extracts has potent phytochemicals properties that has helped to prevent high fructose diet-
induced deposition of fat in the in the liver (non-alcoholic fatty liver disease), without 
compromising growth, visceral morphometry and general health of growing Wistar rats.  
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1.0 Introduction 
 
Urbanisation has led to an increase in the proportion of children and adolescents living sedentary 
lifestyles and consuming artificially sweetened foods, rich in fructose (Rutledge and Adeli, 2007; 
Weiss et al., 2004). The consumption of diets high in fructose has been shown to cause obesity 
and metabolic syndrome in South African adolescents (Steyn and Temple, 2012). Metabolic 
syndrome is a manifestation of various medical conditions (Weiss et al., 2004) that include 
abdominal obesity, atherogenic dyslipidaemia, hypoalbuminaemia, raised blood pressure, insulin 
resistance, glucose intolerance and hypercholesterolaemia (Alberti et al., 2006; Huang et al., 
2004). It has been suggested that obesity is the main driver of increased childhood metabolic 
syndrome, in developing countries (Misra and Khurana, 2008; Kelishadi, 2007). In South Africa 
the prevalence of childhood obesity is estimated to be 7.8% and it is expected to increase to 
22.8% by 2020 (Toriola et al., 2012). The expected increase in childhood obesity will cause an 
increase in the prevalence of metabolic syndrome as a consequence (Mollentze, 2006).  
 
Pharmaceutical drugs such as metformin and fenofibrates are used to manage metabolic 
syndrome (Kraja et al., 2010; Kirpichnikov et al., 2002). Despite the existence of pharmaceutical 
drugs, about 80% of the population in communities in the developing countries rely on medicinal 
plants to treat ailments such as metabolic dysfunction (Fyhrquist et al., 2002). This is due to the 
high cost, limited access and availability pharmaceutical drugs to third world country 
communities. The tree Terminalia sericea (T. sericea) is widely distributed in subtropical Africa 
and is used by traditional healers to treat wounds, stomach problems, hypertension and diabetes 
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mellitus (Mochizuki and Hasegawa 2007; Fyhrquist et al., 2002). Its extracts contain biologically 
and pharmacologically active phytochemicals including tannins, saponins and flavonoids 
(Nkobole et al., 2011; Mochizuki and Hasegawa 2006). Tannins, saponins and flavonoids have 
been demonstrated to have antioxidant, antidiabetic, antimicrobial and cardioprotective properties 
(Sandhar et al., 2011; Subramaniam et al., 2011; Dwivedi 2007; Eckel et al., 2005). T. sericea is 
used in ethnomedicine to treat diabetes mellitus (Fyhrquist et al., 2002), however only in-vitro 
studies have been done to evaluate its hypoglycaemic, antidiabetic and hypolipidaemic properties 
(Nkobole et al., 2011; Mochizuki and Hasegawa, 2006).  
 
1.1 Justification of study 
 
Majority of studies evaluating the antidiabetic and antiobesity potential of medicinal plants used 
streptozotocin-induced diabetic rat models to evaluate the efficacy of the plants (Din et al., 2011; 
Njomen et al., 2009; Rao and Nammi, 2006). Streptozotocin-induced diabetic rat models do not 
efficiently mimic the metabolic syndrome in humans caused by the consumption of diets high in 
refined sugars (Huang et al., 2004) hence it is preferable to use high fructose diet-induced 
metabolic syndrome rat models (Huang et al., 2004). In addition most studies have used adult 
rats and have focused on trying to find curative traditional plants (Njomen et al., 2009; Rao and 
Nammi, 2006). However, the prevalence of metabolic syndrome and obesity has been identified 
to be increasing in children and adolescents (Kelishadi, 2007) hence the need to use growing 
animals (i.e growing rats) modelling the development of diet-induced obesity as well as 
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metabolic dysfunction in children and adolescents (Kohen-Avramoglu et al., 2003) with aim of 
exploring preventative interventions.  
 
Although there are many conventional pharmaceutical drugs that can be used in treating 
metabolic syndrome and obesity, their high cost and poor accessibility especially for third world 
country communities has led to the resurgence of research focusing on indigenous trees and herbs 
as potential treatments for metabolic syndrome (Ayyanar et al., 2008). T. sericea is an indigenous 
tree with multiple ethnomedicinal uses (Deutschlander et al., 2009; Mochizuki and Hasegawa 
2007) including the treatment of diabetes mellitus (Deutschlander et al., 2009; Fyhrquist et al., 
2002). In vitro studies have reported that T. sericea stem bark and root to have anti-diabetic and 
anti-obesity properties (Nkobole et al., 2011; Mochizuki and Hasegawa 2006). T. sericea 
aqueous leaf extracts contain saponins, tannins and flavonoids (Masoko et al., 2005; Bessong et 
al., 2004; Fyhrquist et al., 2002). Saponins, tannins and flavonoids are known to have 
hypoglycaemic, anti-diabetic and lipolytic properties thus T. sericea could have the potential to 
prevent the onset of fructose-induced metabolic dysfunction and obesity. There is little or no 
research that has been done regarding T. sericea leaves as a potential preventative medication for 
high fructose diet-induced metabolic dysfunction and obesity in growing rats modelling human 
children and adolescents.  
 
The first point of contact for orally administered substances is the gastrointestinal tract (GIT) 
(Rubino et al., 2010). Therefore, the first place where the plant extracts exert their effects would 
be in the GIT. The ontogenic development of the GIT has three-stages: the prenatal, neonatal and 
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post-weaning stage (Zabielski et al., 2008). Prenatally there is little stimulation of the GIT lumen 
(Zabielski et al., 2008). Neonatal stimulation is by milk and the post-weaning stage is when the 
switch from milk to solid feed occurs (Zabielski et al., 2008). The post-weaning stage is a critical 
stage in the development of the GIT. The introduction of solid feeds too early (to the not yet 
adapted GIT of infants) increases the risk of developing GIT post-weaning disorders (Zabielski et 
al., 2008). The GIT is vital in the digestion and absorption of nutrients; altering nutrient 
absorption can affect overall growth and development of the growing animal (Pérez et al., 2007). 
 
Compounds found in plant extracts used in ethnomedicines can exert negative or positive effects 
on the nutrient absorptive capacity of the GIT (González-Alvarado et al., 2007; Kochhar et al., 
2007). T. sericea leaves are rich in tannins (Nkobole et al., 2011). Studies have suggested that 
tannins may have detrimental effects on the mucosal layer of the GIT, resulting in reduced 
nutrient absorption and reduced growth in animals (Chung et al., 1998). However, Mochizuki 
and Hasegawa (2007) showed that T. sericea sericosides have protective properties within the 
GIT lumen. Thus, administration of T. sericea orally can potentially have positive or negative 
effects on the development of the GIT, as well as nutrient absorption. Furthermore, medicinal 
plants used in communities are usually folk referrals and are believed to be harmless to the body 
(Erasto et al., 2005). However, medicinal plants have the potential to cause adverse side effects 
such as cytotoxicity (Bussmann et al., 2011; Kane et al., 1995). Hence, when researching 
medicinal properties of plants there is a need to also screen them for toxicity. 
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1.2 Aim of study 
 
The broad objective of the current study was to determine the effects of orally administered 
aqueous T. sericea leaf extracts in high-fructose diet-fed growing Wistar rats. Specifically the 
study sought to determine the effects of orally administered aqueous T. sericea leaf extracts in 
growing Wistar rats on: 
a. growth performance (body mass and indexes of long bone growth). 
b. glucose tolerance.  
c. serum concentrations of metabolic substrates (glucose, triglycerides, free fatty acids and 
cholesterol).  
d. serum insulin concentration and HOMA IR index. 
e. liver glycogen and lipid storage. 
f. the general health profile by determining serum activities of alanine aminotransferase 
(ALT) and alkaline phosphatase (ALP) and other markers (serum creatinine, urea, total 
bilirubin, globulin, calcium, phosphorus, total protein, albumin, cholesterol, and amylase) 
of general health. 
g. GIT and visceral organ macro- and micro-morphometry.  
h. To determine the phytochemical composition and toxicity of aqueous T. sericea leaf 
extracts, using qualitative phytochemical screening and the brine shrimp toxicity assay. 
 
 
7 
 
1.3 Hypothesis 
 
The null and alternate hypotheses of the study were: 
i. H0: Orally administered aqueous T. sericea leaf extracts do not improve the growth 
performance, post-weaning GIT development and have no effect on markers of metabolic 
dysfunction and the general health profile of growing male Wistar rats given a high fructose diet.  
 
ii. H1: Orally administered aqueous T. sericea leaf extracts improve growth performance, post-
weaning GIT development and affect markers of metabolic dysfunction and the general health 
profile of growing male Wistar rats given a high fructose diet. 
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CHAPTER 2: LITERATURE REVIEW 
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2.0 Introduction:  
 
Metabolic syndrome refers to the manifestation of a combination of risk factors (visceral obesity, 
insulin resistance, hyperglycaemia, hypertriglyceridaemia, increased low density lipoprotein, 
decreased high density lipoprotein and hypertension) that increase the chance of developing type 
II diabetes mellitus and cardiovascular diseases (Beilby, 2004). According to the International 
Diabetes Federation guidelines (IDF) and World Health Organisation (WHO) guidelines, 
metabolic syndrome in children and adolescents is diagnosed when patients present with central 
obesity and any other 2 of hyperglycemia, hypertriglyceridaemia, hypertension and decreased 
high density lipoprotein (Friend et al., 2013). In developing countries the number of children and 
adolescents that are obese has been increasing rapidly thus more children and adolescents are at 
risk of developing metabolic dysfunction (Al-Isa, 2013). Metabolic dysfunction is associated 
with altered insulin secretion, insulin resistance and type II diabetes mellitus (Al-Isa, 2013). 
 
2.1 Consequences of metabolic syndrome 
 
Insulin resistance, an inability of target cells to respond appropriately to insulin (Mather et al., 
2007), and hyperglycaemia are the main mediators of the consequences of metabolic syndrome. It 
(insulin resistance) results in hyperglycaemia which leads to dyslipidaemia (Gall et al., 2010). 
The latter is characterised by higher than normal plasma concentrations of triglycerides, 
cholesterol and low density lipoproteins (Li et al., 2011) which is driven by the greater 
esterification of free fatty acids (FFAs) compared to their oxidation (Thirunavukkarasu et al., 
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2004). Increased esterification of FFAs promotes the formation and secretion of triglycerides, 
cholesterol and very low density lipoprotein (VLDL) by the liver (Rutledge and Adeli, 2007; 
Thirunavukkarasu et al., 2004). Very low density lipoprotein (VLDL) is known to be inefficient 
at clearing plasma cholesterol (Thirunavukkarasu et al., 2004), it transports the cholesterol from 
the liver to skeletal and cardiac muscle as well as adipose tissue (Choi and Ginsberg, 2011). The 
increase in triglyceride, cholesterol and non-high density lipoproteins increases inflammatory 
cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) (Wajchenberg et 
al., 2009). An increase in inflammatory cytokines combined with dyslipidaemia, hyperglycaemia 
and insulin resistance can lead to the onset type II diabetes mellitus and its complications 
(LaRosa et al., 2013; Matsudaa and Shimomurab, 2013). 
 
2.1.1 Diabetes mellitus 
 
Worldwide, diabetes mellitus is ranked as the third most common chronic disease in children 
(Pettitt et al., 2013). Diabetes mellitus is a metabolic disorder charecterised by increased blood 
glucose concentration (Pettitt et al., 2013). The two most common subtypes of diabetes mellitus 
are Type I and II diabetes mellitus. Type I diabetes occurs due to autoimmune destruction of β-
cells of the pancreas (Herold et al., 2002) while type 2 occurs due to altered insulin secretion and 
resistance by body tissue (Neergheen-Bhujun et al., 2013). In 2011, an estimated 366 million 
people had diabetes mellitus worldwide. This figure is expected to increase to 552 million by 2030 
(Al-Sarihin et al., 2013). In sub-Suharan Africa, about 12.1 million people had diabetes mellitus 
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(Chen et al., 2011a), with an estimated increase to 23.9 million by 2030 (Chen et al., 2011a; 
Mbanya et al., 2010).  
 
2.1.2 Insulin secretion and complications of type II diabetes mellitus 
 
Insulin is a peptide hormone produced by the β-cells of the endocrine pancreas (Inzucchi and 
Sherwin, 2011). It is a major anabolic hormone that regulates metabolism (Dentin et al., 2007). It 
promotes the uptake and storage of glucose and lipids in the liver, muscle and adipose tissue (Qu 
et al., 2011). The secretion of insulin is stimulated by increase blood glucose concentration (Qu et 
al., 2011). The mechanism of insulin secretion is as summarised in Figure 1.1 below.  
 
Figure1.1: A Schematic representation of the insulin secretion mechanism 
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Glucose enters the β-cell from the blood by facilitation of GLUT 2 transporters (Scheepers et al., 
2004). The increased generation of ATP via glycolysis inside β-cells of endocrine pancreas causes 
the potassium channels to close resulting in an influx of calcium which depolarises the cells and 
subsequently secretes insulin by the β-cells (Scheepers et al., 2004). Source: Beta Cell Biology 
Consortium, 2004; (www.betacell.org/content/articleview/article_id/1/). 
 
In patients with type II diabetes the secretion and action of insulin as well as glycaemic control are 
altered leading to microvascular and macrovascular complications (Donaghue et al., 2009). 
Diabetic retinopathy, a microvascular complication of type II diabetes mellitus, affects 90% of 
diabetic patients (Rotimi et al., 2003). Altered glycaemic control causes progressive retinal vessel 
damage and can ultimately lead to blindness (Cheung et al., 2007; Rotimi et al., 2003). Diabetic 
nephropathy, another microvascular complication in diabetic patients, causes kidney damage that 
can result in renal failure (Donaghue et al., 2009). Macrovascular complications of type II diabetes 
mellitus include coronary heart disease, peripheral vascular disease and stroke (Donaghue et al., 
2009). Coronary heart disease is the major cause of death in type II diabetic patients (Hurst and 
Lee, 2003). Atherosclerosis which causes the stiffening and narrowing of arteries as a result of the 
formation of lipid plaques in the arterial intima is associated with the development of coronary 
heart disease, stroke and hypertension in diabetic patients (Southerland et al., 2012).  
 
Although diabetes mellitus and metabolic syndrome have been well investigated and documented 
using humans and animal models, there still is a need to further investigate ways of preventing 
13 
 
and managing diabetes mellitus, as well as developing experimental models of diabetes mellitus 
and metabolic syndrome. 
 
2.2 Models of metabolic syndrome 
 
The rise in incidence of the metabolic syndrome in children, adolescents and adults has led to the 
development of various research models with the aim of investigating the mechanisms involved 
in the development of metabolic syndrome. The models in use include genetically, chemically 
and diet-induced rat models (Wu et al., 2007; Russell and Proctor, 2006; Bertram and Hanson, 
2001).  
 
2.2.1 Genetic models 
 
Genetic models of components of metabolic syndrome are based on monogenic mutation 
(Bertram and Hanson, 2001) and include the Zucker diabetic fatty rats (fa/fa), db/db 
(C57BL/KsJ-db/db) mice, ob/ob (C57BL/6J-ob/ob) mice, Goto-Kakizaki rats and the Otsuka 
Long-Evans Tokushima fatty rats (Panchal and Brown, 2011; Bertram and Hanson, 2001). The 
rat models are suitable for evaluating the single gene mutation molecular mechanisms involved in 
the metabolic syndrome (Panchal and Brown, 2011). In humans metabolic syndrome is a multi-
factorial disease therefore monogenic rat models are not suitable in mimicking metabolic 
syndrome seen in humans (Lehnen et al., 2013; Buettner et al., 2006). There are newer models of 
metabolic syndrome that are polygenic (Morton et al., 2005). However these polygenic models 
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are also only suitable for studying the specific gene mutation induced components of metabolic 
syndrome. 
 
2.2.2 Pharmacologically-induced models 
 
Chemical models of metabolic syndrome are developed using alloxan or streptozotozin 
(Szkudelski, 2001). Alloxan and streptozotocin are pyramidine glucose analogues which 
selectively destroy the endocrine pancreatic β-cells (Panchal and Brown, 2011; Lenzen, 2008). 
The models in which high doses are used are well suited for investigating type I diabetes 
mellitus, whilst the use of low doses is suited for type 2 diabetes mellitus (Zhang et al., 2008b). 
In an effort to include the dietary complications, researchers have developed models using a 
combination of streptozotocin at low doses and high fat or high fructose diets (Wilson and Islam, 
2012; Bell et al., 2000).  
 
2.2.3 Diet-induced model 
 
Fat, sucrose and fructose are used as dietary ingredients to induce metabolic syndrome in rat 
models (Lehnen et al., 2013; Busserolles et al., 2003). High-fructose diet rat models of metabolic 
syndrome are touted as the best models to use when studying diet-induced metabolic syndrome in 
humans (Oron-Herman et al., 2008), as they cause the development of diverse complications seen 
in humans with diet induced metabolic syndrome (Lehnen et al., 2013).  
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2.2.3.1 Fructose-induced metabolic syndrome: mechanism(s) involved 
 
Fructose is a monosaccharide that requires glucose transporters (Glut 5) to aid its absorption from 
the jejunum (Miller and Adeli, 2008). Once absorbed from the jejunum, fructose is transported to 
the liver where fructose-1-phosphatase mediates its metabolism to 3-carbon molecules: 
glyceraldehyde-3-phosphate and dihydroxyacetone phosphate (Rutledge and Adeli, 2007). These 
3-carbon molecules are used to form triglycerides and free fatty acids (Miller and Adeli, 2008). 
Unlike glucose that activates phosphofructokinase, fructose activates fructose-1-phosphatase 
(Rutledge and Adeli, 2007). Phosphofructokinase is a rate limiting enzyme that will inhibit 
formation of triglycerides from glucose, promote glycogen formation from glucose and stimulate 
insulin secretion (Woo et al., 2010). This means increased absorption of fructose translates into 
increased lipogenesis (Basciano et al., 2005).  
 
Lipogenesis due to high fructose diet consumption results in increased visceral obesity which 
promotes the synthesis and release of tumour necrosis factor alpha (TNF-α) and C-reactive protein 
peptides (Matsudaa and Shimomurab, 2013; Wajchenberg et al., 2009). These inflammatory 
mediators inhibit Glut-4 transporter protein mRNA formation hence decreasing the overall amount 
of Glut-4 receptors which are important for insulin-dependent glucose uptake by tissues 
(Hotamisligil et al., 1994). Decreased Glut-4 receptors lead to inhibition of insulin-activated 
glucose uptake (Jellinger, 2007), depriving them (cells) of the primary source of energy leading to 
their dependence on lipids (secondary) and protein (tertiary) energy stores (Hsu et al., 2012). The 
utilisation of these stores results in elevated plasma triglycerides, free fatty acids and a negative 
nitrogen balance (Hsu et al., 2012). Increased triglycerides and free fatty acids can over-stimulate 
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the pancreas causing increased insulin secretion and later on resulting in lipotoxicity of the 
pancreatic β-cells (Huang et al., 2004). More importantly elevated triglycerides and free fatty 
acids will lead to increased plasma low density lipoproteins, cholesterol and oxidative stress 
(Wajchenberg et al., 2009).  
 
Pharmaceutical drugs such as fenofibrate, metformin, statins, thiazolidinediones and sulfonylurea 
are used to manage the consequences of metabolic syndrome (Florez et al., 2013; Jialal and Smith, 
2012).  
 
2.3 Therapeutic interventions 
 
Fenofibrate, one of the many therapeutic drugs used to manage metabolic syndrome, is a 
hypolipidaemic pharmaceutical drug that lowers cholesterol, triglycerides and low density 
lipoprotein in patients at risk of developing cardiovascular diseases (Ling et al., 2013). A 
derivative of fibric acid, it has a half-life of 20 hours (Tsimihodimos et al., 2005) and acts by 
activating the peroxisome proliferator-activated receptors alpha (PPARα) ligand, thus activating 
genes that regulate lipoprotein lipase, acyl-Co-A oxidase and carnitine palmitoyltranferase (Jeong 
et al., 2004b). Lipoprotein lipase promotes the hydrolysis of plasma triglycerides, whilst acyl-Co-
A oxidase and carnitine palmitoyltranferase promote β-oxidation of free fatty acids, and results in 
inhibition of low density lipoprotein formation (Kraja et al., 2010; Tsimihodimos et al., 2005). 
Fenofibrate also lowers cholesterol by preventing its absorption from the small intestinal lumen 
into the lymph and by promoting HDL formation (Valasek et al., 2007), which (HDL) clears 
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circulating cholesterol. The use of fenofibrate is approved for children and adolescents and is 
known to cause similar beneficial and detrimental effects as seen in adults (Singh, 2006; 
Steinmetz et al., 1981).  
While pharmaceutical drugs such as fenofibrate can be used to manage metabolic dysfunction, 
they are costly and inaccessible to most third world country communities. Traditional medicinal 
plants including Terminalia sericea (T. sericea) thus provide valuable, accessible and affordable 
remedies to 80% of the third world country communities (Fyhrquist et al., 2002).  
 
2.4 Terminalia sericea 
 
T. sericea also known as silver cluster-leaf, and locally as vaalboom, mogonono, moxonono, 
mususu, amangwe, mangwe, mpululu and namatipo (Deutschlander et al., 2009), is widely 
distributed in sub-tropical Africa (Joseph et al., 2007; Fyhrquist et al., 2002). It (T. sericea) 
contains bioactive compounds and is used in ethnomedicine to treat various systemic ailments in 
African communities (Eldeen et al., 2006).  
 
2.4.1 Botanical description 
 
T. sericea is a medium sized deciduous tree that grows up to 9m (Chivandi et al., 2013). Its bark 
is dark grey, thick, fibrous and is longitudinally fissured (Deutschlander et al., 2009). The leaves 
of T. sericea are concentrated on the tips of the shoot and are covered in cottony silver hairs 
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(Deutschlander et al., 2009). The flowers are a pale-yellow or creamy white colour (Chivandi et 
al., 2013). The oval shaped T. sericea fruits are a purplish-red colour when immature and turn 
brown when they mature (Chivandi et al., 2013). 
 
Figure 1.2: The leaves and fruit of T. sericea  
 
2.4.2 Taxonomical classification 
 
T. sericea belongs to the Kingdom Plantae, Division Magnoliophyta, Class Magnoliopsida, Order 
Myrtales, Family Combretaceae, Genus Terminalia and Species sericea (Anderson and Bell, 
(1974). 
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2.4.3 Medicinal uses of Terminalia sericea 
2.4.3.1 Leaves 
 
Leaves of T. sericea are used to treat bacterial infections (Mochizuki and Hasegawa, 2007). Dried 
leaves are used to treat intestinal infections that cause diarrhoea (Mochizuki and Hasegawa, 
2007). In Venda, South Africa, the dried leaf extract of T. sericea is used to manage menorrhagia 
while the dried leaf powder is used to treat infected wounds (Moshi and Mbwambo, 2005; 
Fyhrquist et al., 2002). A decoction of T. sericea plant is used to treat sexually transmitted 
diseases and virility/infertility in males (Moshi and Mbwambo, 2005; Arnold and Gulumian, 
1984).  
 
2.4.3.2 Roots 
 
Hot root infusions are used to treat pneumonia (Deutschlander et al., 2009) and bacterial 
infections (Mochizuki and Hasegawa 2007). In Tanzania the roots are used to manage headaches, 
backaches, diabetes mellitus, diarrhoea and gonorrhoea (Moshi and Mbwambo, 2005). In East 
Africa root decoctions of T. sericea have diuretic properties and are used to treat hypertension, 
bilharziasis and stomach ailments (Fyhrquist et al., 2002). 
 
2.4.3.3 Fruit and bark  
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The T. sericea fruits are used to treat tuberculosis in Malawi (Moshi and Mbwambo 2005; 
Fyhrquist et al., 2002). The stem bark is used to treat diabetes mellitus (Deutschlander et al., 
2009). 
2.4.4 Other uses of Terminalia sericea 
 
Terminalia sericea extracts rich in sericoside are processed and used to produce skin penetrating 
topical cream (Moshi and Mbwambo 2005; Rode et al., 2003). Its wood is used as a fuel energy 
source and building material (Shackleton, 2001). T. sericea plants produce edible gum for 
humans and serve as a source of foraging to browsing herbivores (Aganga et al., 2000; Davidson 
1998). 
 
2.5 Chemical composition of T. sericea 
 
Different parts of T. sericea are composed of various chemical compounds including; 
phytochemicals, fibre, minerals, vitamins, amino acids and free fatty acids (Chivandi et al., 2013; 
Nkobole et al., 2011; Davidson, 1998).  
 
2.5.1 Proximate composition of T. sericea seed 
 
The T. sericea seeds contain 46.2% crude protein and 32.6% lipid (Chivandi et al., 2013). They 
also contain minerals including; phosphorus (1121.75±10.39 mg.100g
-1
 DM), calcium 
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(795.20±17.82 mg.100g
-1
 DM) and magnesium (560.70±6.68 mg.100g
-1
 DM) (Chivandi et al., 
2013). Chivandi et al. (2013) reported that T. sericea seeds contain amino acids with glutamic 
acid (8.07±0.13 g.100g
-1
 DM) being the most concentrated amino acid. The seeds contain 
223.30±2.16 g.kg
-1
 DM and 90.27±4.68 g.100g
-1
 DM neutral and acid detergent fibre, 
respectively (Chivandi et al., 2013).  
 
2.5.2 Lipid profile of T. sericea leaves and seeds 
 
T. sericea leaves and seeds contain saturated, monosaturated and polysaturated fatty acids 
(Chivandi et al., 2013; Davidson, 1998). The most concentrated monosaturated and polysaturated 
fatty acids in T. sericea seed are oleic and α-linolenic, respectively (Chivandi et al., 2013). Whilst 
total lipid content of T. sericea leaves is higher during the dry season than the wet season 
(Davidson, 1998), the saturated and monoenoic fatty acids are highest during the dry season and 
oleic and alpha-linolenic fatty acids are highest during the wet and transition season (Davidson, 
1998). The presence of linoleic acid in the leaves and seeds of T. sericea is suggestive of its 
potential herbal use as an antioxidant and for the management of metabolic dysfunction (Racine 
et al., 2010; Zhang et al., 2008a). 
 
2.5.3 Phytochemical constituents 
 
Tannins, triterpernoid saponins and flavonoids are found in the leaves, bark and roots of T. 
sericea (Nkobole et al., 2011; Mochizuku & Hasegawa, 2006; Bessong et al., 2004). The 
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triterpernoid saponin is made up of sericoside, arjunglucoside and sericic acid (Eldeen et al., 
2006; Rode et al., 2003). Anolignan B, termilignan B and arjunic acid are some of the 
phytochemicals that have been recently isolated in T. sericea ethyl acetate extracts (Eldeen et al., 
2008). Some of these phytochemicals have been identified as the compounds that give T. sericea 
its antimicrobial activity (Eldeen et al., 2008; Eldeen et al., 2006).  
 
2.5.3.1 Tannins  
 
Tannins are naturally occurring polyphenols found in various fruits, vegetables and plants 
(Chung et al., 1998), that have antioxidant properties and lower blood glucose and lipid content 
(Hagerman et al., 1998). They reduce carbohydrate and lipid digestion as well as absorption by 
inhibiting amylases and lipases, respectively (Chung et al., 1998). Tannins derived from 
Terminalia have been demonstrated to promote wound healing (Chaudhari and Mengi, 2006), 
decrease visceral fat, lower blood pressure and prevent free radical induced cardiotoxicity (Singh 
et al., 2008; Dwivedi, 2007); these properties justify the use of T. sericea in ethnomedicine to 
treat diabetes, hypertension and wounds. In vitro studies indicated that tannins can cause 
deterioration of the mucosal lining of the GIT, increase excretion of essential proteins and 
decrease growth performance in mammals, impair glucose transport and decrease vitamin A 
absorption in the intestines (Chung et al., 1998). However in vivo studies have indicated 
contradictory results, showing that tannins have no effect on GIT morphology and excretion of 
essential amino acids (Chung et al., 1998).  
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2.5.3.2 Saponins  
 
Saponins are glycosides that occur naturally in plants and form soap-like foam in water (Wina et 
al., 2005). Triterpenoid saponins, namely lupeol, resveratrol-3-o-B-rutinoside, resveratrol, 
stigmasterol, B-sitoster have been extracted from T. sericea root and bark extracts (Nkobole et 
al., 2011; Joseph et al., 2007; Moshi & Mbwambo, 2005). Saponins decrease blood glucose, 
cholesterol and low density lipoprotein concentration in humans (Mahato, 1988). It is 
hypothesised that T. sericea derived saponins lower blood glucose and cholesterol content by 
stimulating the endocrine pancreatic β-cells to secrete insulin and by inhibiting glucose and 
cholesterol absorption from the GIT (Subramaniam et al., 2011; Francis et al., 2002). Saponins 
have been demonstrated to inhibit glucose uptake in Ehrlich ascites tumour cells (Hasegawa 
1994) and thus inhibit growth of tumour cells, probably by depriving them of nutrients (Francis et 
al., 2002). Furthermore, saponins have scavenging properties that allow them to protect cells and 
cell membranes from damage by free radicals (Eckel et al., 2005). The presence of saponins in T. 
sericea leaves is a probable indicator of its’ extracts to be used in the management of metabolic 
dysfunction. Saponins of T. sericea have been demonstrated to have anti-inflammatory activity 
(Eldeen et al., 2005). Treatment of hypophysial cells with saponins led to increased production of 
luteinising hormone by the cells (Francis et al., 2002). The latter increases production of 
testosterone by testes which is responsible for the development secondary male sex 
characteristics hence this may justify the use of T. sericea in ethnomedicine to treat 
virility/infertility men.  
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2.5.3.3 Flavonoids 
 
Flavonoids are polyphenolic compounds found in plants (Tapas et al., 2008) and are well known 
for their antioxidant activity. Flavonoids, namely rutinoside, catechin, epicatechin, gallocatechin 
and epigallocatechin have been extracted from T. sericea stem bark (Nkobole et al., 2011). Free 
radicals that are bound to flavonoids cannot cause cellular damage (Sandhar et al., 2011). The 
antioxidant and anticoagulant properties of flavonoids prevent vessel endothelial dysfunction, 
thrombosis and cardiovascular diseases (Sandhar et al., 2011). Flavonoids stimulate insulin 
release and pancreas β-cells regeneration (Tapas et al., 2008). They also promote hepatocyte 
regeneration by increasing activity of RNA polymerase I (Tapas et al., 2008), thus suggesting 
that they have potential to treat liver disease. Additionally, flavonoids are cyclooxygenase (COX) 
inhibitors and they can potentially be used as anti-allergy and anti-inflammatory compounds 
(Tapas et al., 2008). 
 
2.6 Pharmacological actions of T. sericea extracts 
2.6.1 Antimicrobial activity 
 
Triterpene saponins, tannins and flavonoids are toxic to microorganisms; they bind to microbial 
cell membranes and impair their functioning (Bowyer et al., 1995; Scalbert, 1991). Both organic 
and aqueous decoctions of T. sericea exhibit antimicrobial activity (Eldeen et al., 2008; Eldeen et 
al., 2006; Moshi and Mbwambo, 2005; Fyhrquist et al., 2002). T. sericea organic and aqueous 
root, stem bark and leaf extracts, in vitro exhibit anti-bacterial activity against Staphylococcus 
aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Enterobacter aerogenes, Bacillus 
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subtilis, Micrococcus luteus, Escherichia coli, Klebsiella pneumonia and Sarcina specie (Eldeen 
et al., 2008; Eldeen et al., 2006; Moshi and Mbwambo, 2005; Fyhrquist et al., 2002). They also 
exhibit antifungal activity against Candida albicans, Aspergillus niger, Aspergillus fumigates, 
Cryptococcus neoformans, Microsporum canis and Sporothrix schenckii (Eldeen et al., 2006; 
Moshi and Mbwambo, 2005; Masoko et al., 2005; Steenkamp et al., 2004; Fyhrquist et al., 
2002). The antimicrobial activity of T. sericea extracts is said to be due to the presence of 
triterpene saponins, tannins, flavonoids and anolignan B (Eldeen et al., 2006; Fyhrquist et al., 
2002).  
 
2.6.2 Anti-HIV activity 
 
Tannins, flavonoids, triterpene saponins, anolignan A and anolignan B are thought to be the 
compounds that give T. sericea its anti-HIV properties (Tshikalange et al., 2008; Wall et al., 
1996). In vitro studies have reported that organic and aqueous T. sericea leaf and root extracts 
have inhibitory properties against human immunodeficiency virus (HIV-1) replication enzymes 
(Tshikalange et al., 2008; Bessong et al., 2004).  
 
2.6.3 Antioxidant activity 
 
Studies have reported that T. sericea aqueous and methanolic stem bark extracts have antioxidant 
activity (Nkobole et al., 2011; Steenkamp et al., 2004). T. sericea aqueous and methanolic bark 
extracts significantly lowered oxidant production in formyl-methionyl-leucyl-phenylalanine 
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stimulated neutrophils (Steenkamp et al., 2004). The antioxidant properties of T. sericea stem 
bark extracts are said to be due to triterpene saponins tannins and flavonoids, which scavenge 
harmful oxidants (Nkobole et al., 2011; Eckel et al., 2005).  
 
2.6.4 Antidiabetic and lipolytic activity 
 
Nkobole et al. (2011) tested the anti-diabetic activity of T. sericea stem bark by measuring 
inhibitory activity of alpha-glucosidase and alpha amylase in an in vitro bioassay. T. sericea stem 
bark extracts showed strong inhibition of alpha-glucosidase and alpha-amylase, thus suggesting 
that it may have anti-diabetic properties. Similarly, Tshikalange et al. (2008) reported inhibitory 
activity T. sericea chloroform, ethyl-acetate and 70% acetone bark extracts on alpha-
glucuronidase and beta-glucuronase. However, an in vivo study by Moshi and Mbwambo (2005) 
reported that administering a single dose (200 mg.kg
-1
 body mass) of 20% aqueous-ethanol T. 
sericea root extracts had no effect on glucose tolerance of Wistar mice. 
 
2.6.5 Anti-inflammatory  
 
Eldeen et al. (2005) reported that ethyl acetate, ethanol and aqueous root and stem bark extracts 
of T. sericea inhibited cyclooxygenase-1, an enzyme key to inflammatory responses. Central 
obesity can induce an inflammatory response that results insulin resistance (Hotamisligil et al., 
1994). Mochizuki and Hasegawa (2007) tested T. sericea roots for their protective effect against 
2,4,6-trinitrobenzesulfonic acid (TNBS) induced inflammatory bowel disease (IBD). The T. 
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sericea sericoside in the roots of T. sericea was reported to have protective effects against TNBS 
induced IBD (Mochizuki and Hasegawa, 2007). Additionally, flavonoids and saponins, present in 
T. sericea extracts have been reported to mitigate inflammation by suppressing mediators of 
inflammation (Eldeen et al., 2008; Eldeen et al., 2006; Eldeen et al., 2005). 
 
2.6.6 Antitumour effect 
 
T. sericea leaf and root extracts have been shown to be cytotoxic to T 24 bladder cancer cell, 
Hela cervical cancer cells and MCF breast cancer cells and thus inhibiting their proliferation 
(Fyhrquist et al., 2006; Bessong et al., 2004). Tannins, saponins and flavonoids, which are 
present in T. sericea extracts, have been implicated as being anti-cancerous agents (Fyhrquist et 
al., 2006; Bessong et al., 2004). 
2.6.7 Toxicity  
 
Plants contain phytochemicals that have the potential to be toxic. It is important to evaluate the 
toxic potential carried by traditional plants. Cytotoxicity of T. sericea dichloromethane, ethyl 
acetate, dichloro:methanol, methanol and ethanol root extracts, have been investigated using 
standard brine shrimp toxicity tests. It was reported that all extracts showed toxicity but 
dichloromethane and petroleum extracts being the exceptions (Moshi and Mbwambo, 2005). 
Bessong et al. (2004) reported that T. sericea aqueous and methanolic extracts showed no 
toxicity in Hela P4 cell lines that were treated with 600 µg.ml
-1
 of the extracts.  
.  
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CHAPTER 3: MATERIALS AND 
METHODS 
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3.0 Source of T. sericea leaves 
 
T. sericea leaves were collected in the summer of 2012 at Maubane N1 toll road, Republic of 
South Africa. The area on latitude 25° 16' 34.13", longitude 28° 17' 55.92" has an average annual 
maximum temperature of 27ºC, mean annual rainfall of 530 mm-650 mm (M’marete, 2003). The 
area (Maubane) is characterised by black clay soils (Coetzee et al., 2003).  
 
The identification of the collected leaves was authenticated by a botanist (Mr Donald McCallum) 
at the University of the Witwatersrand’s Herbarium. A sample of the T. sericea plant was stored 
at the University of the Witwatersrand Herbarium under the reference number J96241. 
 
3.1 Preparation of T. sericea leaf extracts 
 
The leaves were dried overnight in an oven (Salvis 
®
, Salvis Lab, Switzerland) at 40°C (Ahmed 
et al., 2005), after which they were ground to a course powder in a blender (Waring®, Lasec SA, 
Johannesburg, South Africa). The extraction was done using distilled water. Briefly, every 25 g 
of the leaf powder was mixed with 250 ml of boiling distilled water and placed on a shaker for 24 
hours (Bessong et al., 2004). The mixture was filtered twice: firstly through a cheese cloth and 
thereafter through filter paper (Whatmann
®
, No 1 size 50 mm, England) (Bessong et al., 2004). 
The resultant filtrate was concentrated by evaporating at 50
°
C in a rotor vacuum evaporator 
[Labocon (Pty) Ltd, Krugersdorp, South Africa] and then placed in an oven (Salvis 
®
, Salvis Lab, 
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Switzerland) at 40
°
C till they reached dryness after four days. The dry extracts were stored in air 
tight dark glass bottles and kept in a dark cupboard until use. 
 
3.2 Determination of the phytochemical composition of T. sericea leaf extracts 
 
Qualitative tests were used to determine the presence and or absence of flavonoids, terpenoids, 
saponins, tannins and anthraquinones in T. sericea aqueous leaf extracts. 
 
3.2.1 Flavonoids 
 
The presence of flavonoids was determined as described by Doss (2008). Briefly, 2 g of T. 
sericea leaf filtrate was added to 5 ml of 10% ammonium hydroxide in a test tube. Then 1ml of 
concentrated sulphuric acid was added to the mixture. Presence of flavonoids was indicated by 
the development of a yellow colour. 
  
3.2.2 Terpenoids 
 
The presence of terpenoids in the T. sericea leaf extract was determined as described by Ayoola 
et al. (2008). Briefly, 0.5 g of the T. sericea leaf extract was added to 2ml chloroform in a test 
tube following which 3ml of concentrated sulphuric acid was added to the mixture. Development 
of a reddish brown colour in the interface layer indicated the presence of terpenoids. 
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3.2.3 Saponins 
 
The presence of saponins in the T. sericea leaves was determined as described by Ayoola et al. 
(2008). Briefly, 1 ml of T. sericea leaf resultant filtrate was added to 10 ml distilled water in flask 
and shaken for 30 seconds. Frothing confirmed the presence of saponins. 
 
3.2.4 Tannins 
 
The presence of tannins in the T. sericea leaves was determined as described by Ayoola et al. 
(2008). Briefly, 0.5 mg of T. sericea extract was boiled in 5 ml of distilled water in a beaker. 
Ferric chloride was then added. Development of a dark purple black colour showed the presence 
of tannins. 
 
3.2.5 Anthraquinones  
 
The presence of anthraquinones in the T. sericea leaves was determined as described by Ayoola 
et al. (2008). Briefly 5 g of T. sericea extract was boiled in 10 ml 2M sulphuric acid. The mixture 
was then filtered; the resultant filtrate was added to 5 ml chloroform to form two layers. The 
chloroform layer was then carefully pipetted into a test tube containing 1ml of diluted ammonium 
hydroxide and colour changes were observed. 
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3.3 Brine shrimp toxicity assay 
3.3.1 Hatching of nauplii 
 
Cysts of Artemia salina were hatched at room temperature in saline water (2% NaCl) overnight. 
The saline was aerated by bubbling atmospheric air in the hatching container using a 60ml 
syringe connected to an infusion pump (Harvard Apparatus, MA, USA).  
 
3.3.2 Brine shrimp assay 
 
Fifty milligrams (50 mg) of the T. sericea aqueous leaf extracts were dissolved in 5ml 
dimethylsulfoxide and made to 100ml with 2.9% saline solution. The extract solution was serially 
diluted to concentrations of 5000, 500, 50, 5, 0.5 and 0.05 µg.ml
-1
. The extract solutions (2ml) 
were transferred in duplicate to a 24-well plate. Saline solution (2.9%) was used as a negative 
control. Potassium dichromate, which is toxic to brine shrimp, was used as a positive control at 
concentrations of 3000, 300, 30 and 3 µg.ml
-1
. The freshly hatched nauplii were placed in the 
wells (10 per well) followed by incubation at room temperature for 24 hours. The numbers of 
dead nauplii were then counted percentage mortality determined and the half maximal lethal 
concentration (LC50) calculated. 
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3.4 Ethical clearance for use of animals and the study site 
 
The study, conducted in the Central Animal Services (CAS) unit at the Faculty of Health 
Sciences, University of the Witwatersrand, was approved by the Animal Ethics Screening 
Committee (AESC) of the University of the Witwatersrand, Johannesburg, South Africa (AESC 
number: 2012/29/05). Tissue assays were done in appropriate laboratories of the School of 
Physiology, University of the Witwatersrand.  
 
3.5 Animals: feeding and housing 
 
Forty 21-day weanling male Wistar rat pups were used in the experiment. The commercial rat 
chow used in this study was bought from EPOL Animal Feed Manufacturers [Epol
®
, Centurion, 
South Africa (protein 170 g.kg
-1
, fat 25 g.kg
-1
, fibre 70 g.kg
-1
, calcium 25 g.kg
-1
, phosphorus 6 
g.kg
-1
 and total lysine 6.5 g.kg
-1
)]. The pups had ad libitum access to a standard rat chow. Each 
pup was individually housed in a perspex cage with clean wood shavings for bedding. Bedding 
was changed once a week. Room temperature was maintained at 22±2°C with lights on between 
7am to 7pm. The pups were given 3 days familiarisation period before the start of the 
experimental period. 
 
3.6 Treatment doses and drug vehicle medium preparation  
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The dosage of fenofibrate used in the current study was similar to that used by Legendre et al. 
(2002). The low and high dose of the aqueous T. sericea leaf extracts were similar to those used 
by Njomen et al. (2009) and Rao and Nammi (2006). The 2 ml gelatine cubes used as vehicle 
mediums for T. sericea aqueous leaf extract and administration were prepared as described by 
Kamerman et al. (2004). Briefly, 8g of Sheridans, clear, unflavoured edible gelatine [Retailer 
Brands (Pty) Ltd, South Africa], 17 g brown sugar (Sunsweet® Huletts, South Africa) and 5ml 
Beefy Bovril (Bokomo Foods, South Africa) were added to 100ml of warm water and then the 
solution was allowed to cool down and form solid moulds. The Fructose solution was prepared 
by adding commercial fructose (Huletts®, Fructose Concentrated Sweetness, Low GI, South 
Africa) to a litre of warm water in a beaker. Food Colouring [Robertsons, Red Food colouring, 
Retailer Brands (Pty) Ltd, South Africa] was added to the fructose solution to help with 
identification.  
  
3.7 Treatments and experimental design  
 
Forty 21-day old male Wistar pups were randomly allocated to five treatment regimens. Each 
treatment regimen had 8 pups. The pups had ad libitum access to a standard rat chow. Group 1 
pups were given plain gelatine cubes and plain drinking water (PC + PW), group 2: plain 
gelatine cubes and 12% fructose solution (PC + FS), group 3: gelatine cubes containing 
fenofibrate at a concentration calculated to deliver 100 mg.kg
-1
 body mass per day and 12% 
fructose solution (FF + FS), group 4: gelatine cubes containing low dose  of the T. sericea extract 
at a concentration calculated to deliver 100 mg.kg
-1
 and 12% fructose solution (LD + FS) and 
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group 5: gelatine cubes containing high dose of the T. sericea extract at a concentration 
calculated to deliver 400 mg.kg
-1
and 12% fructose solution (HD + FS). The pups were 
maintained on the treatment regimens for 12 weeks. 
 
3.8. Body mass measurement 
 
The rats were weighed (Snowrex Electronic Scale, Clover Scales, Johannesburg) twice per week 
to monitor growth performance. The body mass measurements also allowed for the maintenance 
of a constant dosage of the T. sericea leaf extract and fenofibrate relative to body mass over the 
12-week treatment period. 
 
3.9. Experimental intervention and terminal procedures 
3.9.1 Oral glucose tolerance test 
 
After 12 weeks of treatments the rats were given a 12-hour overnight fasting period before the 
determining their tolerance to an oral glucose challenge. Fasting blood glucose concentrations 
were determined (time interval 0) on each rat using a glucometer calibrated according to 
manufacturer’ instructions (Ascentia, EliteTM, Bayer Corporation, Mishawaka, USA). Blood for 
the fasting blood glucose concentration determination and after an oral glucose challenge was 
taken via a pin prick of the tail vein after sterilisation of the area to be pricked with a cotton 
gauze swab impregnated with alcohol (Loxham et al., 2007). Following the determination of the 
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fasting blood glucose concentrations, rats were gavaged via orogastric intubation with 2g kg
-1
 
body mass of sterile 50% (w/v) D-(+)-glucose solution [Merck Chemicals (Pty) Ltd, 
Johannesburg, South Africa]. Post gavage glucose concentrations at time intervals 15, 30, 60, 
120 and 180 minutes, were then determined as previously described (Leng et al., 2004). 
 
3.9.2 Terminal procedures 
 
Following the OGTT, the rats were put back onto their respective treatments for 48 hours. 
Thereafter, they were fasted overnight and their fasting blood glucose levels were then 
determined (the following morning), using a calibrated glucometer (Ascensia Elite
TM
 Blood 
glucose meter, Bayer Corporation, Mishawaka, USA) according to the manufacturer’s 
instructions. The rats were then euthanased by intra-peritoneal injection with an overdose of 
sodium pentobarbitone (Eutha-naze, Bayer, Johannesburg, South Africa) at 200 mg.kg
-1 
body 
mass. 
 
3.9.2.1 Blood collection, processing and plasma storage 
 
Following euthanasia of the rats, 8ml of blood was collected via cardiac puncture using 21G 
needles and 10ml syringes and divided equally into 4ml plain and 4ml heparin blood tubes 
(Becton Dickinson VACUTAINER Systems Europe, Meylan Cedex, France). A drop of the 
blood was then used to determine fasting blood triglycerides using a calibrated Accutrend 
triglyceride meter (Roche, Mannheim, Germany) according to the manufacturer’s instructions. 
The blood samples were spun for 15 min at 5000 G at 20 
0
C in a Sorvall RT
®
 6000B centrifuge 
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(Pegasus Scientific Inc., Rockville USA). The plasma and serum were collected and then stored 
at -20 
0
C for the analysis of insulin and general health profile markers, respectively. 
 
3.9.2.2 Determination of visceral organ morphometry 
 
Following blood collection, the abdomen was cut open by midline incision. The liver, stomach, 
pancreas, small and large intestines, ceacum, visceral fat, epididymal fat, heart and kidney were 
carefully dissected out. The contents of the stomach, small and large intestines and caecum were 
gently emptied after which the GIT and other viscera were weighed on a Presica 310M electronic 
balance (Presica Instruments AG, Switzerland). The small and large intestines were gently 
stretched out on a board and their lengths were measured using a ruler mounted on a cooled 
dissection board. A sample of the liver was stored at -20ºC for determination of lipid and 
glycogen content. A sample of the liver and small intestine (proximal and distal) were preserved 
in 10% phosphate buffered formalin for histology analysis. The remainder of the liver samples 
were frozen for the determination of liver lipid and glycogen content. The masses of the empty 
carcasses were then determined after. 
  
3.9.2.3 Determination of indexes of long bone growth 
 
The femoral attachment of left hind leg to the pelvis was excised from each of the carcasses, 
defleshed and disarticulated from the tibia. The bones were dried in an oven (Salvis 
®
, Salvis 
Lab, Switzerland) at 50
o
C for 5 days and then weighed after which the tibia (measured between 
tibia head medial malleolus) and femur (measured between distal femoral articular surface to the 
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greater trochanter) lengths were measured with a pair of vernier calipers (Hi-impact, Dejuca, 
South Africa). Bone density was then caluclated using the formula: 
Bone density = mass of bone (mg) /length of bone (mm) 
To further evaluate bone density of tibiae and femora, radiographs were taken using a Fuji film 
X-ray machine (Industrial X-ray film FR, Fuji Photo Film Co, Ltd, Tokyo, Japan). Briefly, the 
bones were placed on the photographic plate at a distance of 1 metre from the X-ray light source 
with settings of 4.8 kVp, 0.71 mA per plate was used.  
 
3.9.2.4 Determination of liver lipid and glycogen storage 
 
Liver lipids were extracted as described by Bligh and Dyer (1959). Briefly, 5g of liver was 
steeped overnight in 150 ml of a 2:1 mixture of chloroform methanol at 4 
o
C. The mixture was 
filtered through filter paper (Whatmann®, No 1, size 185 mm, pore size 7-11μm, England) into 
250ml separating funnel. Then 30ml of 0.9% saline was added to the filtrate and mixed 
thoroughly. The resultant mixture was allowed to stand overnight in a refrigerator at 4
o
C after 
which the organic layer was separated out into round bottomed flask. The organic aliquot was 
reduced to dryness under vacuum at 37
o
C. The lipid extract was dissolved in 20ml chloroform 
and 2 ml of the extract mixture was dried to determine the lipid content in the liver. 
Liver glycogen was determined indirectly by acid hydrolysis to glucose and measurement of 
glucose (Passonneau and Lauderdale, 1974). The glucose concentration of the hydrosylate was 
determined on an Accu-Chek Active glucometer (Roche, Germany).  
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3.9.2.5 Determination of liver and small intestine histomorphometry 
 
The preserved liver and small intestine samples were embedded in paraffin wax, sectioned, and 
then stained with haematoxylin and eosin, on a glass slide and covered with a glass cover slip 
(Reyes-Gordillo et al., 2007). The slides were then viewed under a light microscope using an eye 
piece micrometer (Reichert®, Austria). The height of villi and crypt depth of the small intestines 
were measured. The hepatocyte size and cell numbers within a linear field (100μm) was 
measured at high power magnification of 400X. 
 
3.9.2.6 Determination of biochemical health profile markers 
 
Serum concentrations of ALT, ALP, urea nitrogen, creatinine, total protein, albumin, globulin, 
total bilirubin, phosphorus, calcium, cholesterol and amylase of the rats were determined using a 
colorimetric-based clinical chemistry analyzer (IDEXX VetTest® Clinical Chemistry Analyser, 
IDEXX Laboratories Inc., USA) as per the manufacturer’s instructions. Briefly, each stored 
serum sample was thawed and allowed to warm to room temperature, gently inverted to mix the 
contents and then placed into the analyzer which automatically drew up 150 μL of the serum. Ten 
microlitres (10 μL) of serum were then loaded onto each of the pre-loaded disks after which each 
sample was then analysed and print outs provided. 
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3.9.2.7 Plasma insulin concentration determination 
 
Plasma insulin was determined by enzyme linked immunosorbent assay (ELISA) using a Rat 
insulin kit (DRG ®, Rat Insulin High Range, USA) according to the manufacturer’s instructions. 
The assay employed a quantitative sandwich enzyme immunoassay technique which utilizes a 
monoclonal antibody specific for rat insulin. Absorbencies were read at 450 nm using a plate 
reader (Multiskan Ascent, Lab system, model nº 354, Helsinki, Finland). A standard curve was 
constructed using calibrator concentration sand the concentrations of insulin in the samples were 
determined. A detailed description of the protocol employed is described in appendix 2. 
 
3.9.2.8 Computation of the HOMA IR index  
 
The HOMA-IR used for the assessment of insulin resistance, was computed as shown in the 
equation below: 
HOMA-IR = [fasting insulin (μU.ml-1) × fasting glucose (mmol.l-1)/22.5] (Matthews et al., 1985) 
 
3.10 Statistical analysis 
 
All data are expressed as mean ± SD. Data analysis was done using Graphpad Prism 5 software 
(Graph-pad Software Inc., San Diego, USA). Statistical significance was considered when P≤ 
0.05. Data for weekly body mass and OGTT were analysed using a repeated measures analysis of 
variance while data for other parameters were analysed by a one-way analysis of variance. The 
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Bonferroni post hoc test was used to compare means. The model used for the analysis of variance 
for weekly body masses and the glucose tolerance test was: 
Yijk = μ + Ti + Bj + Ck + eijk; where; 
Yijk = blood glucose concentration at time C post gavage 
μ = overall mean common to all observations 
Ti = effect of treatment (n = 1,2,..5) 
Bj = fixed effect of individual rat (1,2,3.........40)  
Ck = fixed effect of sampling time on blood glucose concentration (= 1,2......6) 
 eijk = residual random error 
The model used for analysis of variance for variables determined at study termination was: 
Yijk = μ + Ti + Bj + eijk; where; 
Yijk = response variable of interest 
μ = overall mean to all observations 
Ti = effect of treatment (n = 1,2,..5) 
Bj = fixed effect of individual rat (1,2,3.........40)  
eijk = residual random error 
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CHAPTER 4: RESULTS 
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4.1 Phytochemical composition of aqueous leaf extract 
 
Table 4.1 shows the phytochemical composition of the aqueous T. sericea leaf extract. 
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Table 4.1 Phytochemical constituents of the aqueous T. sericea leaf extract 
Phytochemical  Present/Absent 
Terpernoids  Present 
Saponins  Present 
Flavonoids  Present 
Tannins  Present 
Anthraquinones Absent 
The aqueous T. sericea leaf extracts contained terpernoids, saponins, flavonoids, and tannins but 
did not appear to contain anthraquinones. 
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4.2 Brine shrimp toxicity assay 
 
Figure 4.1 shows the results of the toxicity test of aqueous T. sericea leaf extracts on brine 
shrimp nauplii. 
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Figure 4.1: Toxicity of aqueous T. sericea extracts on Artemia salina (brine shrimp) nauplii. 
The aqueous T. sericea leaf extracts had a median lethality concentration of (LC50 - 24 hours) of 
97.96±0 µg.ml
-1
.  
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While the median lethality concentration of (LC50 - 24 hours) of aqueous T. sericea leaf extracts 
was 97.96±0 µg.ml
-1
 (Figure 4.1). The LC50 - 24 hours was 3 µg.ml
-1
 for the positive control; 
potassium dichromate (data not shown).  
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4.3 Mortality and morbidity of the rats 
 
During the in vivo study, all the rats remained healthy with no incidental or iatrogenic rat 
mortalities recorded. 
 
4.4 Effects of aqueous T. sericea leaf extract on growth performance 
4.4.1 Body mass and empty carcass mass 
 
Figures 4.2A and 4.2B show the induction and terminal body masses and empty carcass masses, 
respectively, of the rats across the different treatment regimens.  
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Figure 4.2A: The induction and terminal body masses of the rats given the different 
treatments. 
*** P < 0.0001. The induction body masses of the rats were statistically similar (P > 0.05) across 
the different treatments. The terminal body masses of the rats were similar (P > 0.05) across the 
different treatments. Rats in all groups grew significantly (P < 0.0001) compared to their 
induction mass. PC + PW = plain gelatine cube + plain water; PC + FS = plain gelatine cube + 
12% fructose solution; FF + FS = 100 mg.kg
 -1 
body mass per day fenofibrate + 12% fructose 
solution; LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 
12% fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body 
mass per day) + 12% fructose solution. Data presented as mean±SD; n = 8 per treatment.  
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While the induction and terminal body masses of the rats across the treatments were similar (P > 
0.05), rats given each treatment grew significantly (P < 0.0001) compared to their induction body 
masses (Figure 4.2A) 
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Figure 4.2B: Effect of aqueous T. sericea leaf extract on the empty carcass mass of the rats. 
*** P < 0.0001. Rats given FF + FS had significantly (P < 0.0001) lighter empty carcass masses 
compared to empty carcass masses of rats from all treatment groups. Rats given PC + PW, PC + 
FS, LD + FS and HD + FS, respectively, had similar empty carcass mass. PC + PW = plain 
gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; FF + FS = 
100 mg.kg
 -1 
body mass per day fenofibrate + 12% fructose solution; LD + FS = low dose 
aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% fructose solution; HD + 
FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% fructose 
solution. Data presented as mean±SD; n = 8 per treatment.  
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While the empty carcass masses of rats given FF + FS were significantly (P < 0.0001) lower 
compared to the carcass masses of all rats from other treatment groups, rats given PC + PW, PC + 
FS, LD + FS and HD + FS, that had similar (P > 0.05) empty carcass masses (Figure 4.2B).  
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4.4.2 Linear growth 
 
Table 4.2 shows lengths, masses and densities of tibiae and femora of the rats following 
administration of their respective treatments for 12 weeks.  
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Table 4.2: Effect of aqueous T. sericea leaf extract on tibiae and femora lengths, masses and density of the rats 
 n.s. = not significant, P > 0.05. *P ≤ 0.05; **P < 0.01. abWithin row means with different superscripts are significantly different at P ≤ 
0.05. Rats given FF + FS had significantly (P = 0.04) shorter tibiae compared to the tibiae lengths of rats from all treatment groups. 
Rats given LD + FS had significantly (P = 0.0024) heavier tibiae compared to that of rats given FF + FS. Femora lengths and tibiae 
and femora densities of the rats across the different treatments were similar (P > 0.05). PC + PW = plain gelatine cube + plain water; 
PC + FS = plain gelatine cube + 12% fructose solution; FF + FS = 100 mg.kg
 -1 
body mass per day fenofibrate + 12% fructose solution; 
 PC + PW 
 
PC + FS 
 
FF + FS 
 
LD + FS 
 
HD + FS 
 
Significance 
level 
Tibia       
Length (mm) 40.74±0.66
a 
40.51±0.80
a 
39.65±0.71
b 
40.92±0.66
a 
40.56±0.65
a
 * 
Mass (mg) 577.75±31.43
ab 
573.00±35.92
ab 
551.75±26.24
a 
598.5±28.08
b 
585.62±24.68
ab 
** 
Density (mg.mm
-1
) 14.18±0.61
a
 14.15±0.90
a
 13.91±0.57
a
 14.62±0.53
a
 14.43±0.53
a
 ns 
Femur       
Length (mm) 36.45±0.97
a
 35.65±1.70
a
 35.48±0.93
a
 36.34±0.24
a
 37.01±1.55
a
 ns 
Mass (mg) 676.00±36.21
a
 671.5±37.83
a
 653.3±48.26
a
 698.8±21.11
a
 686±32.52
a
 ns 
Density (mg.mm
-1
) 18.54±0.71
a
 18.86±1.08
a
 18.40±0.93
a
 19.23±0.55
a
 18.55±0.85
a
 ns 
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LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% fructose solution; HD + FS = high dose 
aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% fructose solution. Data presented as mean±SD; n = 8 per 
treatment.  
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The rats that received FF + FS had significantly (P = 0.04) shorter tibiae compared to rats from 
all other treatment groups, which (PC + PW, PC + FS, LD + FS and HD + FS) had similar (P > 
0.05) tibiae lengths (Table 4.2). While the rats given FF + FS had significantly (P = 0.0024) 
lighter tibiae compared to their counterparts given LD + FS, rats given other treatments (PC + 
PW, PC + FS and HD + FS) had similar (P > 0.05) tibiae masses (Table 4.2). Femora lengths and 
masses as well as tibiae and femora densities were similar (P > 0.05) across treatment groups 
(Table 4.2).  
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Figure 4.3 shows radiographs of femora and tibiae of the rats after 12 weeks on their respective 
treatments. 
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Figure 4.3: Radiograph images of femora and tibiae of the Wistar rats. 
The top row shows radiographs of the femora of rats from different treatment regimens and the 
bottom row shows the tibiae of representative rats from the different treatment groups. PC + PW 
= plain gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; FF + 
FS = 100 mg.kg
 -1 
body mass per day fenofibrate + 12% fructose solution; LD + FS = low dose 
aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% fructose solution; HD + 
FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% fructose 
solution.  
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There were no observable differences in the radiographical densities of the bones across 
treatment regimens (Figure 4.3).  
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4.5 Effect of aqueous T. sericea leaf extract on glucose tolerance  
 
Figures 4.4A shows the blood glucose concentrations at basal (0 min) and at 15, 30, 60, 120 and 
180 minutes post gavage with 50% percent glucose solution at 2 g.kg
-1
 body mass of the rats 
following 12 weeks on their respective treatment regimens. Figure 4.4B shows the area under the 
curve calculated from oral glucose tolerance test results.  
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Figure 4.4A: Effect of aqueous T. sericea leaf extracts on the glucose tolerance of rats.  
** P < 0.01; *** P < 0.0001. Rats given FF + FS had a significantly higher (P < 0.0001) blood 
glucose concentration compared to all the other treatment groups at all time intervals post gavage, 
except at 60 minutes post-gavage where they (rats given FF + FS) had significantly higher (P = 
0.0006) blood glucose concentration compared to rats given PC + FS. The blood glucose 
concentration of rats given FF + FS significantly peaked (P < 0.0001) at 15 mins post-gavage 
while that of rats given other treatments significantly peaked (P < 0.0001) at 60 mins post 
gavage. PC + PW = plain gelatine cube + plain water; PC + FS = plain gelatine cube + 12% 
fructose solution; FF + FS = 100 mg.kg
 -1 
body mass per day fenofibrate + 12% fructose solution; 
LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% 
fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass 
per day) + 12% fructose solution; Mins = minutes. Data presented as mean±SD; n = 8 per 
treatment.  
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The rats administered FF + FS had a significantly higher (P < 0.0001) basal blood glucose 
concentration and at 15, 30, 120, and 180 min post-gavage compared to rats given other 
treatments (Figure 4.4A). At 60 min post-gavage the rats that were given fructose solution and 
fenofibrate (FF + FS) had significantly (P = 0.0006) higher blood glucose concentration 
compared to their counterparts given plain cubes and fructose solution (PC + FS) (Figure 4.4A). 
While the blood glucose concentrations of rats given FF + FS returned to basal concentration 60 
minutes post-gavage, those given LD + FS and HD + FS returned to basal 180 minutes post-
gavage and those treated with PC + PW and PC + FS remained significantly higher (P < 0.05) 
compared to basal concentrations until 180 minutes post-gavage (Figure 4.4A). 
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Figure 4.4B: Effect of aqueous T. sericea leaf extracts on total area under the curve of oral 
glucose tolerance of rats.  
*** P < 0.0001. Rats treated with FF + FS had significantly (P < 0.0001) higher area under the 
curve of oral glucose tolerance test compared to that of rats from other treatment groups. PC + 
PW = plain gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; 
FF + FS = 100 mg.kg
 -1 
body mass per day fenofibrate + 12% fructose solution; LD + FS = low 
dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% fructose solution; 
HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% 
fructose solution; AUC = Area under curve. Data presented as mean±SD; n = 8 per treatment.  
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The area under the curve of oral glucose tolerance test of rats admintered FF + FS was 
significantly (P < 0.0001) higher compared to the area under the curve of oral glucose tolerance 
test from rats given other treatment regimens, which (rats from other treatment groups) had 
similar (P > 0.05) area under the curve of oral glucose tolerance test (Figure 4.4B).   
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4.6 Effect of aqueous T. sericea leaf extracts plasma insulin concentration and HOMA index  
 
Table 4.3 shows the plasma insulin concentrations and the HOMA-IR indexes of the rats after 
being given their respective treatments for 12 weeks. 
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Table 4.3 Effect of aqueous T. sericea leaf extracts on fasting blood glucose and plasma insulin concentration and HOMA-IR 
index 
 PC + PW 
 
PC + FS 
 
FF + FS 
 
LD + FS 
 
HD + FS 
 
Significance 
level 
Glucose mmol.l
-1 
4.14±0.36
a
 4.01±0.44
a
 5.14±0.54
b
 4.06±0.35
a
 3.95±0.36
a
 *** 
Insulin µg.l
-1 
5.65±2.80
a
 5.32±2.28
a
 5.93±2.21
a
 5.40±1.73
a
 5.21±1.50
a
 ns 
HOMA-IR  1.05±0.55
a
 0.95±0.43
a
 1.34±0.51
a
 0.97±0.33
a
 0.93±0.31
a
 ns 
n.s. = not significant, P > 0.05. ***P < 0.0001
. ab
Within row means with different superscripts are significantly different at P ≤ 0.05. 
Rats given FF + FS had significantly higher (P < 0.0001) fasting glucose concentration compared to all rat treatment groups. The 
plasma insulin concentrations and HOMA-IR were statistically similar (P > 0.05) across for rats from all treatment groups. PC + PW = 
plain gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; FF + FS = 100 mg.kg
 -1 
body mass per day 
fenofibrate + 12% fructose solution; LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% 
fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% fructose solution; 
HOMA-IR = Homeostatic model of insulin resistance. Data presented as mean±SD; n = 8 per treatment.  
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While rats adminitered FF + FS had significantly elevated (P < 0.0001) fasting blood glucose 
concentration compared to that of rats from the rest of the treatments, the plasma insulin 
concentration and the HOMA-IR index were similar (P > 0.05) for the rats across the treatment 
groups (Table 4.3).  
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4.7 Effect of aqueous T. sericea leaf extracts on visceral organs 
 
The effect of the treatments on the absolute and relative masses and lengths (where appropriate) 
of the GIT viscera is shown in Table 4.4A while the masses of the other visceral organs are 
shown in Table 4.4B. 
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Table 4.4A: Effect of aqueous T. sericea leaf extract on GIT visceral organ masses and lengths in male Wistar rats 
Organ  PC + PW 
 
PC + FS 
 
FF + FS 
 
LD + FS 
 
HD + FS 
 
Significance level 
Stomach (g) 1.93±0.13
a
 1.90±0.20
a
 2.18±0.22
a
 2.10±0.27
a
 1.97±0.19
a
 ns 
%BM 0.54±0.03
a
 0.54±0.06
a
 0.64±0.04
b
 0.57±0.05
ab
 0.55±0.04
a
 ** 
TLr (g.mm
-1
) 4.74±0.30
a
 4.70±0.47
a
 5.50±0.57
b
 5.12±0.60
ab
 4.84±0.44
ab
 * 
SI (mm) 1203±40.96
a
 1243±102.4
a
 1223±37.32
a
 1172±89.17
a
 1208±38.91
a
 ns 
SI (g) 7.41±0.71
a
 7.27±0.48
a
 8.38±1.03
b
 7.60±0.60
a
 7.31±0.41
a
 * 
%BM 2.07±0.14
ab
 2.06±0.09
ab
 2.47±0.15
b
 2.08±0.08
ab
 1.80±0.73
a
 ** 
TLr (g.mm
-1
) 18.18±1.58
a
 17.94±1.11
a
 21.14±2.56
b
 18.56±1.24
a
 18.02±0.93
a
 ** 
LI (mm) 248.10±20.34
a
 268.80±14.33
a
 261.30±14.58
a
 254.40±10.16
a
 260.00±18.52
a
 ns 
LI (g) 2.15±0.32
a
 2.02±0.13
a
 2.15±0.27
a
 1.99±0.22
a
 2.04±0.23
a
 ns 
%BM 0.60±0.07
a
 0.57±0.04
a
 0.64±0.09
a
 0.54±0.06
a
 0.57±0.06
a
 ns 
TLr (g.mm
-1
) 5.27±0.77
a
 4.98±0.30
a
 5.41±0.67
a
 4.86±0.51
a
 5.02±0.53
a
 ns 
Caecum (g) 1.48±0.24
a
 1.38±0.25
a
 1.22±0.18
a
 1.33±0.24
a
 1.29±0.24
a
 ns 
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%BM 0.42±0.06
a
 0.39±0.05
a
 0.36±0.05
a
 0.36±0.06
a
 0.36±0.06
a
 ns 
TLr (g.mm
-1
) 3.64±0.53
a
 3.40±0.62
a
 3.08±0.44
a
 1.33±0.24
b
 3.18±0.58
a
 *** 
n.s. = not significant, P > 0.05. * P ≤ 0.05; ** P < 0.01; ***P < 0.0001. abWithin row means with different superscripts are 
significantly different at P ≤ 0.05. Rats adminitered FF + FS had significantly (P < 0.01) heavier (relative to body mass) stomachs 
compared to rats treated with PC + PW, PC + FS and HD + FS. Rats administered FF + FS had significantly (P < 0.05) heavier 
(relative to tibia length) stomachs compared to rats treated with PC + PW and PC + FS. Rats given FF + FS had significantly (P < 
0.05) heavier absolute and relative (to tibia length) small intestine masses compared to all rat treatment groups. Rats given FF + FS had 
significantly (P = 0.002) heavier (relative to body mass) small intestine masses compared to rats given LD + FS. Rats administered the 
LD + FS had significantly (P < 0.0001) lighter caeca (relative to tibia length) compared to other treatment groups. PC + PW = plain 
gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; FF + FS = 100 mg.kg
 -1 
body mass per day 
fenofibrate + 12% fructose solution; LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% 
fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% fructose solution; BM 
= Body mass; LI = Large intestine; SI = small intestine; TLr = Relative tibia length; VFP = visceral fat pad. Data presented as 
mean±SD; n = 8 per treatment. 
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Rats given FF + FS had significantly (P < 0.01) heavier stomachs relative to body mass compared 
to the stomach masses of rats given PC + PW, PC + FS and HD + FS (Table 4.4A). Relative to 
tibia length, rats administered FF + FS had significantly heavier stomachs (P < 0.05) compared to 
the stomach masses of rats treated with PC + PW and PC + FS (Table 4.4A). On the basis of 
absolute and relative to tibia length mass, rats administered FF + FS had significantly (P < 0.05) 
heavier small intestines compared to the small intestinal masses of rats administered other 
treatments (Table 4.4A). However relative to body mass the rats treated with FF + FS had 
significantly (P = 0.002) heavier small intestines compared to that of rats treated with LD + FS 
(Table 4.4A). Relative to tibia length, rats that were given FF + FS had significantly (P < 0.05) 
heavier caeca masses compared rats given other treatments (Table 4.4A). The large intestine 
absolute and relative (body mass and tibia length) masses and small intestine and large intestine 
lengths were similar (P > 0.05) across treatment groups (Table 4.4A). 
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Table 4.4B: Effect of aqueous T. sericea aqueous leaf extract on other visceral organs absolute and relative masses in male 
Wistar rats 
Organs  PC + PW 
 
PC + FS FF + FS 
 
LD + FS 
 
HD + FS 
 
Significance level  
Heart (g) 1.24±0.11
a
 1.24±0.12
a
 1.28±0.14
a
 1.23±0.16
a
 1.16±0.06
a
 ns 
%BM 0.35±0.02
ab
 0.35±0.03
ab
 0.38±0.04
b
 0.35±0.03
ab
 0.32±0.01
a
 * 
TLr (g.mm
-1
) 3.04±0.24
a
 3.06±0.28
a
 3.23±0.36
a
 3.12±0.40
a
 2.87±0.16
a
 ns 
Liver (g) 10.31±1.12
a
 10.56±1.11
a
 16.36±2.01
b
 10.68±1.11
a
 10.42±0.88
a
 *** 
%BM 2.88±0.20
a
 3.00±0.28
a
 4.83±0.32
b
 2.92±0.18
a
 2.92±0.12
a
 *** 
TLr (g.mm
-1
) 25.30±2.70
a
 26.10±3.01
a
 41.25±5.01
b
 23.86±2.66
a
 25.66±1.94 *** 
Pancreas (g) 1.58±0.28
a
 1.47±0.24
a
 1.59±0.30
a
 1.60±0.33
a
 1.55±0.17
a
 ns 
%BM 0.44±0.07
a
 0.41±0.06
a
 0.47±0.10
a
 0.44±0.08
a
 0.43±0.04
a
 ns 
TLr (g.mm
-1
) 3.88±0.67
a
 3.62±0.61
a
 4.00±0.75
a
 3.92±0.83
a
 3.83±0.40
a
 ns 
VFP (g) 5.89±1.57
a
 6.66±1.10
a
 7.51±1.63
a
 7.23±2.32
a
 6.68±1.27
a
 ns 
%BM 1.64±0.37
a
 1.88±0.26
a
 2.21±0.35
a
 1.96±0.54
a
 1.87±0.31
a
 ns 
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EFP (g) 4.86±0.93
a
 4.97±0.84
a
 4.38±1.12
a
 5.46±0.91
a
 4.90±0.68
a
 ns 
%BM 1.36±0.22
a
 1.41±0.23
a
 1.28±0.25
a
 1.50±0.18
a
 1.37±0.18
a
 ns 
Kidney (g) 2.53±0.24
a
 2.44±0.12
a
 2.90±0.26
b
 2.51±0.24
a
 2.50±0.16
a
 *** 
%BM 0.71±0.04
a
 0.69±0.03
a
 0.86±0.03
b
 0.68±0.04
a
 0.70±0.04
a
 *** 
TLr (g.mm
-1
) 6.22±056
a
 6.01±0.36
a
 7.30±0.60
b
 6.13±0.59
a
 6.17±0.38
a
 *** 
n.s. = not significant, P > 0.05. *P ≤ 0.05, ***P < 0.0001. abWithin row means with different superscripts are significantly different at P 
≤ 0.05. Rats administered FF + FS had significantly (P = 0.0132) heavier relative (to body mass) hearts masses compared to the mass 
of the hearts of rats administered HD + FS. Rats given FF + FS had significantly (P < 0.0001) heavier livers (absolute and relative to 
body mass and tibia length) compared to the liver masses of rats given the other treatments. Rats administered FF + FS had 
significantly (P < 0.0001) heavier kidneys (absolute and relative to body mass and tibia length) compared to the kidney masses from 
rats administered other treatments. PC + PW = plain gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose 
solution; FF + FS = 100 mg.kg
 -1 
body mass per day fenofibrate + 12% fructose solution; LD + FS = low dose aqueous T. sericea leaf 
extract (100 mg.kg
-1
 body mass per day) + 12% fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 
body mass per day) + 12% fructose solution; BM = Body mass; EFP: Epididymal fat pad; TLr = Relative tibia length. Data presented 
as mean±SD; n = 8 per treatment.  
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While absolute heart masses across all treatment groups was similar (P > 0.05), relative to body 
mass rats administered FF + FS had significantly (P = 0.0132) heavier hearts compared to the 
heart masses of rats administered HD + FS (Table 4.4B). Relative to body mass and tibia length, 
rats that were administered FF + FS had significantly (P < 0.0001) heavier kidneys and livers, 
respectively, compared to the kidney and liver masses from rats received other treatments (Table 
4.4B). The visceral fat pad, epididymal fat pad, pancreas and testicular masses were similar (P > 
0.05) across all treatment groups (Table 4.4B).  
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Table 4.4C shows the villi height, crypt depth and ratio of the villi heights to crypt depths of the 
rats given the different treatments. The mean hepatocyte size and number of hepatocytes per 
100µm linear field is shown in Table 4.4D. 
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Table 4.4C: Effect of aqueous T. sericea aqueous leaf extract on villi height, crypt depth and the villi height: crypt depth ratio 
in male Wistar rats 
 PC + PW 
 
PC + FS FF + FS 
 
LD + FS 
 
HD + FS 
 
Significance level 
VH (µm) 51.83±2.42
a
 65.00±5.77
a
 66.12±7.95
a
 62.5±3.53
a
 58.5±9.19
a
 ns 
CD (µm)  18.75±2.16
a
 19.50±1.00
a
 17.25±0.35
a
 17.75±4.95
a
 19.00±0.35
a
 ns 
VH/CD ratio 2.76±1.12
a
 3.30±5.71
a
 3.83±0.54
a
 3.52±0.71
a
 3.08±26.26
a
 ns 
n.s. = not significant, P > 0.05. 
ab
Within row means with different superscripts are significantly different at P ≤ 0.05. Villus height, 
crypt depth and the villus height: crypt depth ratios of the rats were similar (P > 0.05) across treatment groups. PC + PW = plain 
gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; FF + FS = 100 mg.kg
 -1 
body mass per day 
fenofibrate + 12% fructose solution; LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% 
fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% fructose solution; VH 
= Villus height; CD = Crypt depth. Data presented as mean±SD; n = 8 per treatment.  
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Table 4.4D: Effect of aqueous T. sericea leaf extract on hepatocyte size and density of male Wistar rats 
Liver PC + PW 
 
PC + FS FF + FS 
 
LD + FS 
 
HD + FS 
 
Significance level 
Hepatocyte size (µm)  9.37±0.90
a
 9.22±0.41
a
 9.81±0.54
a
 9.53±0.55
a
 9.67±0.84
a
 ns 
 
Hepatocytes (cells per 100 µm) 
 
10.53±0.90
a
 
 
10.81±1.31
a
 
 
10.41±0.48
a
 
 
11.59±1.63
a
 
 
12.13±1.46
a
 
 
ns 
n.s. = not significant, P > 0.05. 
ab
Within row means with different superscripts are significantly different at P ≤ 0.05. The number of 
intact hepatocytes in a linear field (100 µm) and hepatocyte size were statistically similar (P > 0.05) across all rat treatment groups. PC 
+ PW = plain gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; FF + FS = 100 mg.kg
 -1 
body mass 
per day fenofibrate + 12% fructose solution; LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 
12% fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% fructose solution. 
Data presented as mean±SD; n = 8 per treatment.  
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The villi height, crypt depth, villi height:crypt depth ratio, hepatocyte cell size and numbers of 
hepatocytes in a 100µm linear field were similar (P > 0.05) across all treatment groups (Tables 
4.4C and 4.4D).  
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4.8 Effect of T. sericea aqueous leaf extracts on hepatic metabolic substrates  
 
Figures 4.5A and 4.5B show liver glycogen (represented as glucose equivalents in the liver 
homogenate) and lipid content respectively, of the rats after being given their respective 
treatments for 12 weeks.  
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Figure 4.5A: Effect of aqueous T. sericea leaf extracts on the hepatic glycogen content of 
male Wistar rats.  
Hepatic glycogen (represented as glucose equivalents in the liver homogenate) contents was 
statistically similar (P > 0.05) in the rats across the different treatment groups. PC + PW = plain 
gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; FF + FS = 
100 mg.kg
 -1 
body mass per day fenofibrate + 12% fructose solution; LD + FS = low dose 
aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass per day) + 12% fructose solution; HD + 
FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% fructose 
solution. Data presented as mean±SD; n = 8 per treatment.  
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Figure 4.5B: Effect of aqueous T. sericea leaf extracts on the hepatic lipid content of male 
Wistar rats.  
* P ≤ 0.05; ** P < 0.01. Rats given PC + FS and those given LD + FS had significantly (P = 
0.0032; P = 0.0114, respectively) higher lipid yield (percentage liver mass) compared to rats 
given PC + PW (control). PC + PW = plain gelatine cube + plain water; PC + FS = plain gelatine 
cube + 12% fructose solution; FF + FS = 100 mg.kg
 -1 
body mass per day fenofibrate + 12% 
fructose solution; LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body mass 
per day) + 12% fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 
mg.kg
-1
 body mass per day) + 12% fructose solution. Data presented as mean±SD; n = 8 per 
treatment.  
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While the liver glycogen (represented as glucose equivalents in the liver homogenate) content of 
the rats across treatments were similar (P > 0.05; Figure 4.6B), rats that were given the plain 
gelatine cubes + 12% fructose solution (PC + FS) and their counterparts on a low dose of the 
aqueous T. sericea leaf extract + 12% fructose solution (LD + FS) had significantly higher (P = 
0.0032; P = 0.0114, respectively) hepatic lipid content compared to rats that were given PC + PW 
(control) (Figure 4.6B). 
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4.9 Effect of aqueous T. sericea leaf extract on general health profile  
 
Table 4.5 shows the effects on the markers of the general health of the rats following a 12 week 
administration of their respective treatments.  
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Table 4.5 The effect of aqueous T. sericea leaf extracts on serum markers of general health in male Wistar rats 
 
Parameter PC + PW 
 
PC + FS 
 
FF + FS 
 
LD + FS 
 
HD + FS Significance 
level 
 
ALT (U.L
-1
) 
 
64.13±10.96
a
 
 
70.25±18.61
a
 
 
80±20.80
a
 
 
69.13±10.60
a
 
 
70.25±21.31
a
 
 
ns 
ALP (U.L
-1
) 112.6±23.65
a
 109±19.12
a
 347.40±103.6
b
 101.4±19.26
a
 102±10.70
a
 *** 
TBIL (mg.dL
-1
) 0.4±0.10
a
 0.42±0.14
a
 0.46±0.13
a
 0.46±0.12
a
 0.38±0.08
a
 ns 
Globulin (g.dL
-1
) 2.01±0.45
a
 1.99±0.64
a
 1.71±0.80
a
 2.09±0.55
a
 1.76±0.50
a
 ns 
Albumin (g.dL
-1
) 3.41±0.54
a
 3.65±0.62
a
 4.05±0.76
a
 3.82±0.44
a
 3.82±0.42
a
 ns 
Total protein 
(g.dL
-1
) 
5.45±0.45
a
 5.62±0.54
a
 5.77±0.76
a
 5.91±0.40
a
 5.57±0.45
a
 ns 
BUN (mg.dL
-1
) 19.88±2.85
a
 22.50±2.78
a
 23.88±1.55
a
 23.13±2.36
a
 23.25±3.65
a
 ns 
Creatinine  
(mg.dL
-1
) 
 
0.40±0.07
a
 0.40±0.12
a
 0.38±0.19
a
 0.40±0.13
a
 0.45±0.09
a
 ns 
Calcium (mg.dL
-1
) 10.64±0.94
a
 10.88±1.13
a
 11.19±2.04
a
 11.06±1.20
a
 11.01±0.82
a
 ns 
Phosphorus 
(mg.dL
-1
) 
5.46±0.87
a
 5.74±0.51
ab
 6.82±1.16
b
 6.22±0.83
ab
 5.54±0.95
ab
 * 
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Continued  
Amylase (U.L
-1
) 1349±271.9
a
 1522±232
a
 1588±306.4
a
 1495±114.2
a
 1424±51.98
a
 ns 
Triglycerides 
(mmol.l
-1
) 
1.23±0.35
a
 1.53±0.37
a
 1.29±0.30
a
 1.38±0.27
a
 1.53±0.29
a
 ns 
Cholesterol 
(mg.dL
-1
) 
69.75±10.74
a
 75.38±14.70
a
 75.38±31.30
a
 74.38±17.44
a
 74.25±10.47
a
 ns 
* P ≤ 0.05; *P < 0.05; ***P < 0.0001. abWithin row means with different superscripts are significantly different at P < 0.05. Rats 
administered FF + FS had significantly (P < 0.0001) higher serum ALP concentration compared to the serum ALP in rats given other 
treatments. Rats adminitered FF + FS had significantly (P = 0.0346) higher serum phosphate concentrations compared to that of rats 
given PC + PW. PC + PW = plain gelatine cube + plain water; PC + FS = plain gelatine cube + 12% fructose solution; FF + FS = 100 
mg.kg
 -1 
body mass per day fenofibrate + 12% fructose solution; LD + FS = low dose aqueous T. sericea leaf extract (100 mg.kg
-1
 body 
mass per day) + 12% fructose solution; HD + FS = high dose aqueous T. sericea leaf extract (400 mg.kg
-1
 body mass per day) + 12% 
fructose solution; ALP = Alanine phosphatase ALT = Alanine aminotransferase; BUN = Blood urea nitrogen; TBIL = Total bilirubin. 
Data presented as mean±SD; n = 8 per treatment.  
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Rats that were given FF + FS had significantly (P < 0.0001) elevated serum ALP concentrations 
compared to the serum ALP concentrations of rats from other treatment groups (Table 4.5). The 
serum phosphate concentration from rats given FF + FS was significantly (P = 0.0346) elevated 
compared to that from rats given PC + PW (Table 4.5). Other serum markers of the general 
health profile were similar (P > 0.05) across the treatments (Table 4.5). 
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CHAPTER 5: DISCUSSION 
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The discussion focuses on the phytochemical composition of aqueous T. sericea leaf 
extracts, in vitro toxicity of the aqueous T. sericea leaf extract, effects of the leaf extracts 
on the growth performance, glucose tolerance and HOMA-IR index, GIT viscera and other 
visceral organs, hepatic metabolite storage and the general health profile of growing male 
Wistar rats allowed to drink 12% fructose solution ad libitum.  
 
5.1 Phytochemical constituents 
 
Bessong et al. (2004) reported the presence of triterpene saponin and tannins in organic T. 
sericea leaf extracts while Nkobole et al. (2011) noted organic stem bark T. sericea 
extracts to contain triterpene saponin, tannins and flavonoids. Although this study 
investigated, qualitatively, the phytochemical composition of the aqueous T. sericea 
extract, results of the current study are in agreement with the findings of Nkobole et al. 
(2011) and Bessong et al. (2004). Triterpene saponins, tannins and flavonoids, which were 
reported present in the aqueous leaf extract of the current study, are hypothesised to give T. 
sericea extracts antioxidant, lipolytic an antidiabetic properties (Subramaniam et al., 2011; 
Singh et al., 2008: Tapas et al., 2008). The presence of the phytochemicals (triterpene 
saponins, tannins and flavonoids) in the T. sericea extracts points to potential antioxidant, 
lipolytic and hypoglycaemic properties. 
 
5.2 In vitro toxicity on Brine shrimp nauplii 
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Our Animal Ethics Screening Committee (AESC) does not permit the use of animals in 
toxicity studies, therefore the Brine shrimp toxicity assay served as a proxy to screen the 
potential toxicity of the aqueous T. sericea extracts before use in rats. In the current study 
aqueous T. sericea aqueous leaf extracts were not toxic to brine shrimp nauplii with LC50 
of (97.96 µg.ml
-1
 after 24 hours (Figure 4.1), which is above the 20 µg.ml
-1 
cytotoxic cut 
off point stated by Moshi and Mbwambo (2005). Moshi and Mbwambo (2005) reported 
that aqueous T. sericea root extracts were highly toxic to brine shrimp nauplii with LC50 of 
5.4 µg.ml
-1
. Findings of the current study on low toxicity to brine shrimp of aqueous T. 
sericea leaf extracts are corroborated in the findings of the general health profile of the 
rats, as will be discussed later in this dissertation. Futhermore, these findings suggest that 
aqueous T. sericea leaf extracts could be used in ethnomedicine with a reduced possibility 
of them causing toxicity.  
 
5.3 Growth performance 
5.3.1 Body mass 
 
Body mass can be affected by hydration state, GIT content fill and visceral organ size 
(Owens et al., 1995), thus making it an inaccurate indicator of growth performance. Empty 
carcass mass is a good indicator of growth (lean) performance (Owens et al., 1995). In the 
current study the administration of PC + PW, PC + FS, LD + FS and LD + FS had no 
effect on empty carcass masses. However the administration of FS+FS caused a decrease 
in empty carcass mass of the rats. These findings suggest that while the administration of 
fenofibrate to rats fed 12% fructose solution caused a reduction in the empty carcass mass, 
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while administration of both a low and high dose aqueous T. sericea leaf extracts to rats 
fed a 12% fructose solution had no negative effect on the empty carcass mass.  
 
5.3.2 Linear growth 
 
Long bones grow in response to growth hormone in a dose-dependent manner (Rol De 
Lama et al., 2000), thus making them a better proxy for the estimation of growth 
performance (Sanchez and He, 2009; Han et al., 1965; Butler et al., 1956). The rats that 
were given FF + FS had significantly shorter tibiae compared to the tibiae lengths from rats 
given other treatment regimens (Table 4.2). Additionally they had lighter tibiae compared 
to their counterparts given LD + FS (Table 4.2). These findings suggest that the 
administration of 100 mg.kg
-1
 body mass per day of fenofibrate to rats fed a 12% fructose 
solution might have adverse effects on lengths of tibia. However the similarity in tibiae and 
femora densities (as determined by computation and by radiography), from rats across 
treatments (Table 4.2 and Figure 4.3) suggest that the effects of fenofibrate on linear 
growth need further investigation. 
 
5.4 Glucose tolerance, HOMA-IR and plasma insulin 
 
Previous studies have reported that in rats, high fructose diets cause hyperglycemia, 
glucose intolerance, hypertriglyceridaemia, hypercholesterolaemia and insulin resistance 
(Atanasovska et al., 2009; Huang et al., 2004). The similarities in the fasting blood glucose 
concentrations (Table 4.3; Figure 4.4A), glucose handling after an oral glucose challenge 
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(Figure 4.4A and 4.4B), area under curve of oral glucose tolerance test, plasma insulin 
concentration, HOMA-IR (Table 4.3), fasting blood triglyceride and cholesterol (Table 
4.5) of rats given the control (PC + PW), PC + FS, LD + FS and HD + FS indicates that a 
12% fructose solution administered for 12 weeks to growing male Wistar rats did not cause 
hyperglycaemia, impaired glucose handling, hypertriglyceridaemia, hypercholesterolaemia 
and insulin resistance. The current study results are at variance with the reported 
hyperglycaemia, hypertriglyceridaemia and insulin resistance reported in adult Wistar rats 
after administration of a 10% fructose solution for 8 weeks (de Moura et al., 2009). 
However, in a study on the effect of age on markers of metabolic syndrome in Wistar rats, 
Ghezzi et al. (2012) reported that at ages 2 to 6 months the rats had lower serum 
concentrations of glucose, triglycerides, total cholesterol, HDL and LDL compared to their 
12-month old counterparts. At study termination the rats in the current study were 3.75-
months old, thus were still in the age group where the rats were reported to have lower 
serum markers of metabolic syndrome (Ghezzi et al., 2012). The failure to develop signs 
(glucose intolerance, hypertriglyceridaemia, insulin resistance and hypercholesterolaemia) 
of metabolic syndrome by rats in the current study after being administered with a 12% 
fructose solution for 12 weeks could be attributed to their age. de Moura et al. (2009) 
hypothesised that young Wistar rats may have protective mechanisms against fructose-
induced metabolic syndrome however, they did not provide insight into the specific 
mechanisms that could be responsible. Further investigations are thus required in order to 
establish the underlying mechanisms.  
 
It was observed in the current study that the administration of fenofibrate for 12 weeks at 
100 mg.kg
-1
 body mass per day to growing Wistar rats fed a 12% fructose solution resulted 
in decreased glycaemic control as evidenced by significantly higher fasting blood glucose 
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concentration (Table 4.3) and failure to effectively control blood glucose concentrations 
following an oral glucose load (Figure 4.4A and 4.4B) by rats that were given FF + FS. Liu 
et al. (2011) reported that the administration of 100 mg.kg
-1
 body mass per day of 
fenofibrate for 12 weeks in monosodium glutamate-induced obese rats decreased glucose 
stimulated insulin release and worsened their ability to handle glucose. While fenofibrate is 
reported to cause inflammation and oxidative stress to the pancreas which results in 
decreased insulin secretion (Liu et al., 2011) and decreased ability to handle glucose, the 
decreased glycaemic control and hyperglycaemia in the rats given FF + FS suggests that 
the administration of the fenofibrate may have affected pancreatic β-cell function.  
 
The administration of 100 mg.kg
-1
 fenofibrate for 9 days to 8-10 week old male Wistar rats 
with hypertriglyceridaemia reduced plasma triglyceride concentration (Ferreira et al., 
2008). In the current study, the administration of fenofibrate at a similar dose for 12 weeks 
to rats fed a 12% fructose had no effect on blood triglyceride concentration. A study by 
Furuhashi et al. (2002) showed that fenofibrate (30 mg.kg
-1
) administration for 6 weeks to 
12-week old Sprague-Dawley rats with insulin resistance improved peripheral insulin 
sensitivity; in the present study similarity in the HOMA-IR index of the rats given 
fenofibrate and that of their counterparts on other treatments suggested that fenofibrate had 
no effect on insulin sensitivity.  
 
In the present study, the low and high dose of aqueous T. sericea leaf extracts had no effect 
on the fasting blood glucose, triglyceride, insulin and glucose handling of growing male 
Wistar rats. Tannins, saponins and flavonoids in Terminalia species extracts have been 
shown to reduce fasting blood glucose concentrations, improve glucose handling, insulin 
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sensitivity and β-cell function in streptozotocin-induced diabetic rats (Latha and Daisy 
2010; Tapas et al., 2008; Murali et al., 2007; Nagappa et al., 2003; Francis et al., 2002). In 
vitro studies by Nkobole et al. (2011) and Tshikalange et al. (2008) attributed the 
antidiabetic properties of T. sericea to the bioactive constituients- tannins, saponins and 
flavanoids found in it. Findings of the current study, (fasting blood glucose, glucose 
tolerance test and HOMA-IR indexes) suggest that despite the presence of tannins, 
saponins and flavonoids in aqueous T. sericea leaf extracts, administration of both a low 
and high dose of the leaf extracts had no effect on fasting blood glucose and triglyceride 
concentration and insulin sensitivity by peripheral tissue. 
 
5.5 Visceral organs 
5.5.1 GIT visceral organs 
 
Nutrients are mainly absorbed in the small intestine. An increased villi height:crypt depth 
ratio indicates increased absorptive ability (Metges, 2010). The development of the 
different parts of the GIT can be affected by dietary consumption (Metges, 2010). 
Fenofibrate administration to 3-month old PPARα null mice at dose 800 mg.kg-1 in feed 
for 10 days has been shown to alter gene expression in the intestine (Valasek et al., 2007) 
which translated to reduced lipid absorption (Uchida et al., 2011; Valasek et al., 2007) and 
increased height of villi in the small intestine (Uchida et al., 2011; Valasek et al., 2007). In 
the current study, the oral administration of fenofibrate (100 mg.kg
-1
 body mass per day) 
for 12 weeks to rats fed a 12% fructose solution resulted in increased absolute and relative 
(to body mass and tibia length) small intestine mass (Table 4.4A) but had no effect on 
villus height and crypt depth (Table 4.4C). The effects of fenofibrate on the small intestine 
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could have been due to altered digestion and absorption resulting in an accumulation of 
nutrients the intestine, which might (nutrient accumulation), have resulted in stretching of 
the small intestine tissues and thus their increased masses (Tormo et al., 2004; Younes et 
al., 2001). However, the mechanism by which fenofibrate increased the small intestine 
mass of growing rats given 12% fructose solution requires further investigation. The 
current study reports that whilst administration of fenofibrate (100 mg.kg
-1
 body mass per 
day) resulted in increased relative (to body mass) stomach mass; administration of low 
dose (100 mg.kg
-1
 body mass per day) of aqueous T. sericea extract resulted in increased 
relative (to tibia length) caeca mass in Wistar rats fed 12% fructose solution. However 
these finding could have been due to the differences in body mass and tibia length that the 
relative values were calculated from. Tannins have been reported to erode the GIT mucosal 
layer (Chung et al., 1998) and thus interfere with the digestive and absorptive function of 
the GIT. In the current study, the administration of aqueous T. sericea leaf extracts that 
contained tannins for 12 weeks had no negative effect on growth performance (body mass 
and linear), suggesting that GIT’s digestive and absorptive function was not compromised 
hence nutrients were availed to support growth. 
 
5.5.2 Other viscera 
 
High fructose diets are known to have the potential to cause cardiovascular and renal 
system complications, such as microvascular and muscular tissue hypertrophy (Dachani et 
al., 2012; Gersch et al., 2007; Sánchez-Lozada et al., 2007). Furthermore, they are known 
to increase liver mass and visceral fat pad mass (London and Castonguay, 2011; Huang et 
al., 2004). In the current study following the administration of PC + FS to rats for 12 
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weeks, no changes in absolute and relative masses of the heart, kidney, visceral fat pad, 
epididymal fat pad, liver and pancreas were observed in growing Wistar rats. However, 
following the administration of FF + FS for 12 weeks, results of the current study point to 
increased heart relative (to body mass) masses in the growing Wistar rats (Table 4.4B) 
which are suggestive of increased cardiac tissue. Similar results were reported by Duhaney 
et al. (2007) where fenofibrate administration was found to result in increased ventricular 
hypertrophy in wild-type FVB mice. Thus, findings from the current suggest that the oral 
administration of fenofibrate might have adverse effect on the heart mass of Wistar rats 
given a standard rat chow but given a 12% fructose solution. However, since there were no 
statistically significant differences absolute masses of the hearts from the rats across 
treatments, this finding requires further investigation.  
 
Fenofibrate has been shown to be reno-protective in metabolic syndrome models using 
adult mice and rats (Tanaka et al., 2011; Park et al., 2006). Results of the current study 
revealed that administration of fenofibrate (100mg.kg
-1
 body mass per day) for 12 weeks to 
growing Wistar rats fed a 12% fructose solution, caused a significant (P < 0.05) increase in 
absolute and relative (to body mass and tibia length), in the masses of their kidneys (Table 
4.4B). Kidney hypertrophy could be a result of microvascular infiltration of the kidney 
tissue which has potential to cause kidney disease, thus results of the current study seem to 
contradict the reported reno-protecitve effects of fenofibrate (Tanaka et al., 2011; Park et 
al., 2006).  
 
Price et al. (1986) reported that fenofibrate can result in hepatomegally within 3 days of 
administration in rats. Hong et al. (2007) reported that the administration of fenofibrate 
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at100mg.kg
-1
 body mass per day for 6 weeks to adult male Sprague-Dawley rats resulted in 
hepatomegally. Clinical studies have demonstrated that fenofibrate causes inflammation of 
the liver which in turn leads to hepatomegally (Tolman, 2000). In the current study, the 
administration of fenofibrate (100mg.kg
-1
 body mass per day) for 12 weeks to growing 
male Wistar fed a 12% fructose solution caused a significant increase in absolute and 
relative (to body mass and tibia length) liver mass which might be indicative of 
hepatomegally (Table 4.4B), but without affecting hepatocyte size and the number of 
hepatocytes in a linear field (Table 4.4D). Results the current study are in agreement with 
the finding reported by Gasa (2012), Hong et al. (2007), Harano et al. (2006) and Price et 
al. (1986) also reported that fenofibrate causes hepatomegally. 
 
The tannins, saponins and flavonoids of Terminalia arjuna and Terminalia chebula have 
been shown to be protective to the heart, kidney, liver and pancreas in alloxan-induced 
diabetic rats, adult male Wistar, NZW albino and Swiss albino rats (Muhammad et al., 
2012; Raghavan and Kumari, 2008; Sinha et al., 2008; Manna et al., 2006; Gauthaman et 
al., 2005; Suchalatha and Shyamala, 2004; Gauthaman et al., 2001; Dwivedi and Agarwal, 
1994). In the current study following administration of aqueous T. sericea leaf extracts at 
low (100 mg.kg
-1
 body mass per day) and high (400 mg.kg
-1
 body mass per day) doses for 
12 weeks to growing Wistar rats fed a 12% fructose solution, no changes in absolute and 
relative masses of the heart, kidney, visceral fat pad, epididymal fat pad, liver and pancreas 
were observed. These finding suggests that aqueous T. sericea leaf extracts might have no 
adverse effects on these viscera. 
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5.6 Liver metabolic substrate storage and markers of general health  
 
The liver has several functions including: metabolite storage, bile production, protein 
synthesis, and inactivation of chemical messengers and detoxification (Govind, 2011; Salie 
et al., 1991). High fructose diets are known to cause liver diseases by altering the 
metabolism of carbohydrates and lipids that leads to derangement of homeostasis 
(Rutledge and Adeli 2007; Thirunavukkarasu et al., 2004). Conventional drugs and 
ethnomedicines may contain contaminants and toxins which are processed and detoxified 
in the liver and may have the potential to negatively influence liver function (Basha et al., 
2012; Hajdu et al., 2009; Tasduq et al., 2006; Manna et al., 2006). It is therefore important 
to measure surrogate markers of liver function when ethnomedicines are used. 
 
5.6.1 Liver glycogen content 
 
Feeding a high-fructose diet to Wistar rats has been reported to reduce glycogen synthesis 
in the liver through reduced sensitivity to insulin by hepatocytes, which translates to 
decreased glucose uptake by the cells (Bezerra et al., 2001). Decreased glucose uptake by 
hepatocytes results in reduced glycogen synthesis (Kumar et al., 2006). Yadav et al. (2007) 
reported that administering 21% fructose solution for 8 weeks to 8-week old Wistar rats 
significantly increased their liver glycogen content. In the current study following 
administration of respective treatments for 12 weeks, no differences were observed in the 
liver glycogen content of rats given to the control (PC + PW), PC + FS and those on the 
low (LD + FS) and high (HD + FS) dose aqueous T. sericea leaf extract and those given 
fenofibrate (FF + FS). These findings suggest that the 12% fructose solution, fenofibrate 
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(100 mg.kg
-1
 body mass per day), and low (100 mg.kg
-1
 body mass per day) and high (400 
mg.kg
-1
 body mass per day) aqueous T. sericea extracts did not affect fasting liver 
glycogen content of Wistar rat. Fasting is known to cause liver glycogen depletion 
(Gutman and Shafrir, 1964). The similarity in the liver glycogen content from the rats 
across treatments could have been due to the depletion of the liver glycogen stores, since 
the rats were fasted overnight prior to euthanasia. Future studies should consider 
investigating glycogen stores of rats in the fed state.  
  
5.6.2 Liver lipid content 
 
High fructose diets are known to cause increased lipid synthesis and storage by the liver, 
viscera and muscles (Le et al., 2009; Bergheim et al., 2008; Le et al., 2006). In the current 
study administration of PC + FS and LD + FS for 12 weeks resulted in increased hepatic 
lipid content in growing Wistar rats (Figure 4.5B). This finding suggests that the 12% 
fructose solution induced increased lipid storage by the liver which can potentially cause 
fatty liver disease. Fatty liver disease is a liver-based manifestation of the development of 
metabolic syndrome (Song et al., 2013; de Moura et al., 2009). Fenofibrate is a lipid 
lowering drug (Staels et al., 1998) and has been shown to reduce hepatic lipid synthesis 
and storage in 10-week old Wistar rats (Ferreira et al., 2008). The current study reports 
similar results, that fenofibrate inhibited high fructose diet induced lipid accumulation in 
the liver (Figure 4.5B). In vitro studies have shown that triterpene saponin extracted from 
T. sericea root has lipolysis promoting properties (Mochizuki and Hasegawa 2006). In the 
current study the high dose of aqueous T. sericea leaf extract inhibited the fructose diet 
induced accumulation of lipids in the liver (Figure 4.5B) suggesting that at a high dose, the 
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aqueous T. sericea leaf extracts might prevent accumulation of lipids in the liver, thus 
exhibiting protective potential against diet induced fatty liver disease.  
5.6.3 Markers of liver function 
 
Alanine aminotransferase (ALT) is a surrogate biomarker for intra-hepatic damage (Thulin 
et al., 2008). Alkaline phosphatase (ALP) is a biomarker that indicates post-hepatic liver 
damage or increased bone formation if plasma concentrations are elevated (Pratt and 
Kaplan, 2000; Reichling and Kaplan, 1988). Bilirubin is processed to a soluble state by the 
liver and then excreted in urine and faeces. Elevated concentrations of bilirubin can be 
indicative of red blood cell hemolysis or liver damage (Pratt and Kaplan, 2000). Albumin 
and globulin are major serum proteins that are synthesized by the liver. Decreased albumin 
and globulin serum concentrations are indicative of end-stage liver disease amongst other 
diseases (Oettl et al., 2013).  
 
In rats, high fructose diets have been reported to induce non-alcoholic fatty liver disease 
(NAFLD). The latter (NAFLD) has been implicated as one of the causes of increased 
serum ALT transaminase (de Catro et al., 2013). Interestingly, while other research has 
noted that high fructose diets led to increased fat deposition in the liver and subsequent 
NAFLD (Castro et al., 2011; Kanuri et al., 2011), it could be inferred from this current 
study that although the feeding of a 12% fructose solution to growing Wistar rats for 12 
weeks caused “fatty” livers, it did not result in increased serum ALT and ALP 
concentrations (Table 4.5).  
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The administration of fenofibrate has been shown to cause an increase in serum ALT and 
ALP concentration (Hajdu et al., 2009; Ho et al., 2004) due to hepatocellular damage 
(Tolman, 2000). Interestingly, Cindoruk et al. (2007) reported that administration of 
fenofibrate reduced serum total bilirubin, ALT and ALP in adult male Wistar rats with 
obstructive liver disease. Results of the current study showed that the administration of 
fenofibrate (100 mg.kg
-1
 body mass per day) for 12 weeks to growing Wistar rats fed a 
12% fructose solution caused increased serum ALP concentration (Table 4.5), thus 
suggesting possible hepatic damage by fenofibrate. However, that fact that other serum 
markers of liver function (ALT, total bilirubin, albumin and globulin) were not affected 
suggest that the elevated ALP could have been from bone or intestinal cells (Wolf, 1999), 
since high bone turnover in growing animals is associated with increased serum 
concentrations of ALP (Pratt and Kaplan, 2000; Wolf, 1999; Reichling and Kaplan, 1988). 
Syversen et al. (2009) reported that PPARα increases osteoblast activity which in turn 
results in elevated blood ALP. An isoenzyme of ALP is also found in intestinal cells 
(Wolf, 1999), thus the increased blood ALP in rats given FF + FS could have been due to 
the increased intestinal tissue which was noted in the current study. The specific isoenzyme 
of ALP that was increased was not identified in the current study. Further investigations 
are required to identify the possible source (liver, bone and liver) of the increased blood 
ALP concentration following fenofibrate administration to growing rats.  
 
Terminalia species (T. chebula, T. arjuna and T. brownii) have hepatoprotective properties 
and are used in ethnomedicine to treat liver diseases (Basha et al., 2012; Manna et al., 
2006; Tasduq et al., 2006). Manna et al. (2006) showed that aqueous extracts of T. arjuna 
stem bark lowered serum ALP in Swiss-albino rats with carbon tetrachloride induced liver 
injury. In the current study the low and high dose of aqueous T. sericea leaf extracts had no 
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effect on serum albumin, ALT and ALP concentrations of growing Wistar rats fed 12% 
fructose solution, which suggests that the oral administration of aqueous T. sericea leaf 
extracts did not cause liver damage further confirming the in vitro findings using the brine 
shrimp nauplii. 
 
5.6.4 Markers of kidney function 
 
Creatinine and blood urea nitrogen (BUN) are excreted by the kidney (Chen et al., 2011b). 
Elevated serum concentrations of creatinine and BUN indicate renal complications or 
increased muscle catabolism (Chen et al., 2011b; Cavalcanti et al., 2006). In adult 
Sprague-Dawley rats high fructose (60% w/w) feeds consumed over a 6-week period have 
been demonstrated to cause kidney damage and decrease their ability to filter, thus 
increasing blood creatinine and BUN concentrations (Gersch et al., 2007). In the current 
study the administration if 12% fructose solution for 12 weeks had no effect on serum 
creatinine and BUN, suggesting that the renal function of the rats’ kidneys (across 
treatments) was not compromised.  
 
Chronic use of fenofibrate is known to increase serum creatinine and BUN in humans 
(Chen et al., 2011b). However the mechanisms by which it causes this are still not fully 
understood. Researchers have suggested that fenofibrate possibly reduces glomerular 
filtration (Chen et al., 2011b). In the current study there was no elevation of serum 
creatinine and BUN concentrations from the growing Wistar rats following administration 
of fenofibrate (100 mg.kg
-1
 body mass per day) for 12 weeks, suggesting that fenofibrate 
did not reduce glomerular filtration. 
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Terminalia arjuna aqueous stem bark extract has been shown to protect the kidneys against 
oxidative stress induced damage (Manna et al., 2006) whilst Terminalia bellerica organic 
fruit extract administration to adult Streptozotocin diabetic rat for 60 days, reduced serum 
creatinine and urea (Latha and Daisy, 2010). In the current study, administration of 
aqueous T. sericea leaf extracts for 12 weeks did not affect serum creatinine and BUN in 
growing Wistar rats suggesting that T. sericea aqueous leaf extracts had no adverse effects 
on kidney function. 
 
5.6.5 Effect on serum calcium and phosphorus concentrations  
 
Calcium and phosphorus can be absorbed from the GIT or kidneys and are involved in 
bone formation and mineralization. Their serum concentration are mainly regulated via 
parathyroid and calcitonin hormone but are also be influenced by diet (de Paula and Rosen, 
2010). Calcium and phosphorus concentrations can thus be indicative of bone activity 
(resorption and formation), GIT mineral absorption and kidney mineral absorption and 
secretion. Fructose has been shown to cause kidney damage that can result in increased 
calcium and phosphorus excretion (Taylor and Curhan, 2008; Levin et al., 2007). In the 
current study the administration of PC + FS did not result in increased excretion of the two 
minerals suggesting that there was no damage to the nephrons. However results of the 
current study show that the administration of fenofibrate (100 mg.kg
-1
 body mass per day) 
for 12 weeks to growing Wistar rats fed a 12% fructose solution resulted in increased 
serum phosphorus concentration (Table 4.5). This could have been due to increased 
absorption in GIT and or reabsorption in the kidney. However, further research needs to be 
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conducted to investigate mechanisms by which fenofibrate increased serum phosphorus. 
Tannins are known to have potential to reduce the absorption of minerals (calcium and 
phosphorus) and proteins from the GIT (Muhammad and Oloyede, 2004). Although in the 
current study it was qualitatively established that the aqueous T. sericea leaf extracts 
contained tannins, the similarity in the serum calcium and phosphorus concentration in rats 
which were given both a low and high dose of the aqueous T. sericea leaf extracts for 12 
weeks suggests that the tannins in the extract did not negatively affect their absorption 
from the GIT.  
 
5.6.6 Effect on serum cholesterol  
 
Elevated serum cholesterol levels are associated with various systemic diseases such as 
metabolic syndrome, diabetes mellitus and cardiovascular diseases (Neuschwander-Tetri 
and Wang, 2013). While the oral administration of a 21% fructose solution in 8-week old 
Wistar rats for 8 weeks caused elevated serum cholesterol concentrations (Yadav et al., 
2007), in the current study the oral administration of 12% fructose solution for 12 weeks 
did not cause hypercholesterolaemia in growing Wistar rats. Fenofibrate is known to 
reduce serum cholesterol by inhibiting lipid absorption in the gut and promoting lipid 
oxidation (Valasek et al., 2007; Jeong et al., 2004b). In the current study, no changes in 
serum cholesterol concentration were observed following the oral fenofibrate 
administration for 12 weeks in growing Wistar rats given a 12% fructose solution. 
Saponins and tannins from Terminalia arjuna are known to lower cholesterol synthesis by 
inhibiting lipid absorption and synthesis in the gut and liver, and by increasing high density 
lipoprotein synthesis (Ram et al., 1997; Tiwari et al., 1990). T. sericea aqueous leaf 
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extracts that were administered to growing Wistar rats for 12 weeks contained saponins 
and tannins; however they did not affect serum cholesterol concentrations. It should be 
noted that the effects of the treatments on serum cholesterol could have been affected by 
the fact that the rats were not on a high fat diet.  
5.6.7 Effect on serum amylase activity 
 
Amylases which catalyse the hydrolysis of starch and glycogen to glucose are found in 
saliva and exocrine pancreatic secretions. Their serum concentrations can be used as 
markers of inflammation of the salivary gland or pancreas (Huang et al., 2004; Pieper-
Bigelow et al., 1990). Amylases are targets for diabetes medications: inhibition of 
amylases reduces glucose absorption and thus reducing hyperglycaemia (Hasenah et al., 
2006). Huang et al. (2004) observed that in 7-week old Sprague-Dawley rats given a high-
fructose (60%) diet for 8 weeks did not affect serum amylase concentrations. Similarly 
results of the current study show that oral administration of 12% fructose solution for 12 
weeks had no effect on serum amylase concentration in growing Wistar rats. This suggests 
that 12% fructose solution did not cause inflammation to the salivary glands and pancreas. 
Furthermore administration of fenofibrate had no effect on the amylase concentration in 
growing Wistar rats, suggesting that oral administration of fenofibrate did not cause 
pathology in salivary glands and or that of the pancreas. While findings from the in vitro 
research done by Nkobole et al. (2011) showed that T. sericea stem bark tannins, saponins 
and flavonoids inhibit amylase, in the current study, in vivo, aqueous T. sericea leaf 
extracts had no effect on amylase serum concentration in growing Wistar rats. The effects 
of T. sericea on amylases and carbohydrate absorption in vivo need to be further 
investigated.  
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CHAPTER 6:  CONCLUSION AND 
RECOMENDATIONS 
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6.0 Conclusion and recommendations 
 
The study evaluated the phytochemical composition of aqueous T. sericea leaf extracts, 
toxicity of the aqueous T. sericea leaf extract in vitro, effects of the administration of the 
aqueous leaf extracts on the growth performance, glucose tolerance and HOMA-IR index, 
GIT viscera and other visceral organs, hepatic metabolite storage and the general health 
profile of growing male Wistar rats fed 12% fructose solution. Using qualitative methods, 
T. sericea leaf extracts were found to contain pharmacologically active phytochemicals and 
to be non-toxic to Brine shrimp nauplii. Future studies should quantify the phytochemical 
constituents of the aqueous T. sericea leaf extracts and investigate the toxicity of aqueous 
T. sericea leaf extracts in vivo.  
 
Findings of the current study showed that while the oral administration of a 12% fructose 
solution for 12 weeks to growing male Wistar rats resulted in the development of a “fatty 
liver”, one of the markers of metabolic syndrome, it did not cause the development of 
hyperglycaemia, hypertriglyceridaemia, hypercholesterolaemia, insulin resistance and 
central obesity, which are the other markers of metabolic syndrome. The administration 
fenofibrate and high dose of T. sericea extracts protected against the development of a high 
fructose diet-induced fatty liver. The mechanisms of how the high dose of T. sericea 
extracts protected against development of a “fatty liver” need to be further investigated in 
non-alcoholic fatty liver disease and obesity models. The protective effects of aqueous T. 
sericea leaf extracts can be further exploited clinically in the prevention and possibly 
treatment of patients with fatty liver disease. The oral administration of a low dose (100 
mg.kg
-1
 body mass per day) and high dose (400 mg.kg
-1
 body mass per day) of aqueous T. 
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sericea leaf extracts did not negatively affect growth performance (body mass, empty 
carcass mass and indexes of long bone growth).  
While the administration of aqueous T. sericea leaf extracts did not improve glucose 
handling following an oral glucose challenge, the extracts had no adverse effect on the 
rats’ glucose tolerance, plasma insulin concentration, visceral organ morphometry and on 
markers of general health profile of the rats. These observations suggest that aqueous T. 
sericea leaf extracts could be used in ethnomedicine without an increased risk of 
compromising the glycaemic control, growth performance, GIT and other viscera’s 
morphometry and general health. The oral administration of fenofibrate (100 mg.kg
-1
 body 
mass per day) to growing Wistar rats fed a 12% fructose solution for 12 weeks reduced 
empty carcass, reduced linear growth of the tibia, caused hyperglycaemia, possible liver 
injury and increased mass of visceral organs (small intestine, liver and kidney) in growing 
Wistar rats. The adverse effects of the chronic administration of fenofibrate on tibia bone 
growth, blood glucose homeostasis and liver function enzymes need to be further 
investigated at a cellular and molecular level.  
 
6.1 Limitations 
  
In the current study administration of 12% fructose solution ad libitum resulted in 
increased liver lipid (“fatty liver”) however, no other signs of metabolic dysfunction in 
growing Wistar rats were observed possibly due to it not providing enough excess calories. 
Therefore future studies should consider using fructose solution at a higher concentration 
and possibly supplementing the standard rat chow with lard, to increase calorie and fat 
intake. The present study used male rats only, future studies should consider investigating 
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the effects of orally administered aqueous T. sericea extracts and fenofibrate in male and 
female rats fed normal rat chow and plain water as this will allow for an investigation of 
the effects of the extracts on normal rats of different rat genders. They (future studies) 
should also consider investigating and comparing the effects of T. sericea organic extracts 
to aqueous extracts. Additionally, future studies should also investigate the effects of oral 
administration of aqueous T. sericea leaf extracts on nutrient absorption from the GIT. 
While the current study did not employ molecular techniques to elucidate some of the 
mechanisms that may have been at play, it is recommended that future studies include 
molecular techniques in order to get measurements gene and protein expression level as 
this would helps better explain the mechanisms behind the findings of the study. Other 
technical limitations include that only qualitative and not quantitative phytochemical 
analyses were performed on T. sericea leaf extracts and that subjective assessment of 
radiographs was done to analyse bone density of the rats. Future studies should perform 
quantitative analyses on T. sericea leaf extracts and also do densitometry to analyse bone 
density of the rats. While it would have been interesting to investigate the effects of 
aqueous T. sericea leaf extracts alone, the current study was more focused on the effects of 
fructose induced changes as opposed to general effects of aqueous T. sericea leaf extracts 
which would have required a different experimental design.       
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